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Summary 
The proper and precise regulation of gene expression is crucial for all cellular 
processes. In particular it is a major task for regulating the eukaryotic genome to not only 
control single genes but in addition to simultaneously regulate chromosomal domains that are 
widely spread. A powerful model to study the selective regulation of an entire chromosome is 
the process of dosage compensation in the common fruit fly Drosophila melanogaster. 
The precise activation of gene expression from the single male X chromosome 
requires the selective recruitment of the dosage compensation complex (DCC) to the male X 
chromosome. However, the mechanism by which the DCC distinguishes the X from the other 
chromosomes is poorly understood. It is thought that a subcomplex consisting of the core 
proteins MSL2 and MSL1 serves as a binding module, which initially recognizes so-called 
high affinity sites on the X chromosome. Despite extensive in vivo characterization, a direct 
interaction of the MSL2-MSL1 subcomplex with high affinity sites has not been shown.  
Therefore a purified system consisting of recombinant MSL proteins and synthetic 
nucleic acid structures was established to quantitatively measure their interaction in vitro. The 
MSL2 protein was identified as the DNA binding factor within the MSL2-MSL1 complex. 
For DNA binding MSL2 required its CXC domain, to which so far no function had been 
assigned. The relevance of this DNA binding function was confirmed in vivo: The CXC 
domain was required for MSL2 recruitment to a reporter gene and for the proper targeting of 
the DCC to the X chromosome in Drosophila cells. Moreover, with MSL2 being able to bind 
RNA, a novel RNA binding protein within the DCC has been identified.  
However, MSL2 bound DNA in a sequence-independent manner, indicating that for 
selective binding additional factors might be required. This is supported by the finding that in 
contrast to the Drosophila system, in a heterologous reporter gene system MSL2-MSL1 could 
not activate transcription. In summary, the DNA binding activity by MSL2 is crucial, 
nevertheless, for achieving binding specificity additional targeting principles must be 
involved.  
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Zusammenfassung 
Die korrekte und genaue Regulation der Genexpression ist unabdingbar für alle zellulären 
Prozesse. Insbesondere bei der Regulation des eukaryotischen Genoms ist es eine schwierige 
Aufgabe nicht nur einzelne Gene, sondern auch chromosomale Domänen, die weit verteilt 
sind, gleichzeitig zu regulieren. Ein geeignetes Modell, um die Selektion und Regulation 
eines ganzen Chromosoms zu untersuchen, ist der Prozess der Dosis Kompensation in der 
Fruchtfliege Drosophila melanogaster.      
Die genaue Aktivierung der Genexpression des einzelnen männlichen X Chromosoms 
bedarf der selektiven Rekrutierung des Dosis Kompensations Komplexes (dosage 
compensation complex, DCC) zum männlichen X Chromosom. Jedoch ist der Mechanismus, 
durch den der DCC das X von den anderen Chromosomen unterscheidet, nur unzureichend 
aufgeklärt. Man geht davon aus, dass ein Teilkomplex bestehend aus den Proteinen MSL2 
und MSL1 als Bindungsmodul dient, welches anfänglich sogenannte high affinity sites auf 
dem X Chromosom erkennt. Trotz der umfangreichen Charakterisierung in vivo, wurde eine 
direkte Interaktion des MSL2-MSL1 Teilkomplexes mit high affinity sites noch nicht gezeigt. 
Deshalb wurde ein gereinigtes System etabliert, welches sich aus rekombinanten MSL 
Proteinen und synthetischen Nukleinsäure-Strukturen zusammensetzt, um deren Interaktion 
quantitativ in vitro zu messen. Das MSL2 Protein wurde als der DNA-bindende Faktor 
innerhalb des MSL2-MSL1 Komplexes identifiziert. Zur DNA-Bindung benötigt MSL2 seine 
CXC Domäne, für die bisher keine Funktion bekannt war. Die Relevanz dieser DNA-
Bindungsfunktion wurde auch in vivo bestätigt: Die CXC Domäne war für die Rekrutierung 
von MSL2 zu einem Reportergen und für das korrekte targeting des DCC zum X Chromosom 
in Drosophila Zellen notwendig. Daneben wurde durch die Erkenntnis, dass MSL2 auch 
RNA zu binden vermag ein weiteres potentielles RNA-Bindungsprotein innerhalb des DCC 
identifiziert. 
Jedoch bindet MSL2 DNA auf eine Sequenz-unabhängige Weise, was darauf hindeutet, 
dass für die selektive Bindung zusätzliche Faktoren gebraucht werden könnten. Dies wird 
durch das Ergebnis unterstützt, wonach MSL2-MSL1, im Gegensatz zum Drosophila System, 
in einem heterologen System nicht die Transkription aktivieren konnten. Zusammenfassend 
konnte gezeigt werden, dass die DNA-Bindungsaktivität von MSL2 notwendig ist, um jedoch 
Bindungsspezifität zu erreichen, bedarf es zusätzlicher Faktoren oder Mechanismen, die es 
noch aufzuklären gilt.       
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1 Introduction 
The discovery of the DNA as the heritable information and the deciphering of the genetic 
code, which turned out to be a rather simple four ‘letter’ code, in the middle of the 20th 
century truly marked milestones and opened undreamed-of possibilities. The sequencing of 
the complete genome of various organisms, including our own at the beginning of the 21st 
century, allowed obtaining a genetic ‘blue print’. But on the other hand it became clear that 
just knowing the ‘blue print’ is by far not sufficient to understand the complexity of cellular 
processes. It is in fact the usage, that is the realization of the genetic information, which 
enables a cell to carry out its specific function. This becomes obvious when one thinks about 
a multi-cellular organism with all its many different cell types. They all carry the identical 
genetic information, but it is the differential gene expression, which leads to their different 
morphology and their different functions.  
The proper control of gene expression is therefore a major task for all organisms. Factors, 
like the correct time point or time window (e.g. a specific environmental stimulus or 
developmental stage) or the correct place (e.g. a specific tissue), for switching a gene on or 
off have to be considered. In addition simply switching a gene from off-state to on-state is 
mostly insufficient and much too imprecise to meet the exact needs of a cell. Instead the 
expression of genes has to be fine-tuned and tightly regulated to achieve a precise level of 
expression. Another problem arises from the large number of several thousand genes, which 
have to be controlled. Genes whose expression has to be modulated have to be selected from 
the huge genome, while all others have to stay untouched. In particular for the more complex 
organized eukaryotic genome it is a big challenge to not only select a single or a small group 
of (for example functionally related) genes but in addition to simultaneously regulate 
chromosomal domains that are widely spread over hundreds or thousands of kilobases of 
DNA.  
A powerful model to study two of the above-mentioned challenges, that is the 
selectivity of genes and their precise regulation, is the process of dosage compensation in the 
common fruit fly Drosophila melanogaster. Dissecting this process allows insight into how 
one particular chromosome, namely the single male X chromosome, and almost all of its 
residing genes are selected, while all the other chromosomes are unaffected and secondly how 
the expression of those selected genes is tightly limited to a two-fold activation.  
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1.1 Dosage Compensation 
Sexual reproduction occurs quite frequently in nature. It increases genetic variability 
with every generation and hence allows a population to better cope with environmental 
changes, which is the basis for evolutionary success [1]. However, the emergence of different 
sex chromosomes to define the male and female sex would – without a compensatory 
mechanism – lead to a chromosomal imbalance: The sex with two X chromosomes would 
have the double amount of X-linked gene products as compared to the other sex with only a 
single X and a single gene-poor Y chromosome. This huge difference of several thousand 
gene products between the sexes of the same species would be lethal and therefore has to be 
corrected by a process called dosage compensation. In general three possibilities exist to 
compensate the effect of XX vs. XY; and indeed examples for all three mechanisms are found 
in nature (Figure 1-1 and [2, 3]). In mammals one of the two X chromosomes of females is 
inactivated and consequently genes from that X chromosome are switched off. Another 
possibility is realized in the nematode Caenorhabditis elegans, where the transcription from 
both X chromosomes is halved, whereas in Drosophila melanogaster transcription is doubled 
from the single male X chromosome. In all three cases the result is the same, namely 
equalized levels of gene products between the sexes. However, this compensation leaves the 
imbalance between the X and the autosomes untouched. To ensure a balance between the 
single X and the autosomes also in C. elegans and in mammals, a global upregulation of the 
active X compared to autosomes is postulated [4-6]. Yet, each compensation system made use 
of and adapted special existing systems and machineries; consequently the underlying 
mechanisms for the precise gene regulation and for the selection of the correct chromosome 
differ tremendously.  
 
 
Figure 1-1: Strategies of dosage compensation. To equalize gene expression between the sexes, different 
strategies of dosage compensation have evolved: In humans and other mammals one of the two X chromosomes 
of females is inactivated. In C. elegans gene expression from both X chromosomes of the hermaphrodite sex is 
reduced by 2-fold. In Drosophila melanogaster transcription from the single male X chromosome is two-fold 
upregulated. Numbers represent the gene dose from the single chromosomes.     
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1.2 Modulation of chromatin structure 
The dosage compensation systems are based on different mechanisms, nevertheless all 
make use of principles that allow modulating the structure and organization of chromatin in 
order to regulate gene expression. How this is achieved in general will be discussed in this 
chapter, details can be found later in the individual sections.  
 The organization of the eukaryotic genome into chromatin allows on the one hand 
packaging DNA into the cell nucleus, on the other hand it restricts accessibility of DNA for 
all biological processes, such as replication, DNA repair and transcription. Chromatin is not a 
rigid structure, on the contrary it is highly dynamic and can be altered by various principles, 
such as the modification of histones, the use of histone variants and the action of chromatin 
remodeling machines [7].  
Histones, which represent as nucleosomes (histone octamer with DNA that is wrapped 
around) the basic unit of chromatin (Figure 1-2), can be heavily modified, especially at their 
N-terminal tails [8]. Known posttranslational modifications are among others 
phosphorylation, methylation, ubiquitylation and acetylation. These modifications can be set 
(by ‘writers’) and also deleted by histone-modifying enzymes (‘erasers’) and might either 
influence directly the compaction of chromatin, as discussed later for the acetylation at lysine 
16 of histone H4, or indirectly by serving as recognition signals to attract specific effector 
proteins (‘readers’) (Figure 1-2 and [9]). Additionally, the conventional core histones can be 
replaced by histone variants. Some histone variants differ in their N- or C-terminal tails, 
making them differently susceptible to histone modifications. Histone variants can also affect 
the structure and properties, like mobility or stability of the nucleosome and in this way might 
influence the overall dynamics of chromatin [7]. Nucleosomes that contain the histone variant 
macroH2A, which is found on the inactive X chromosome in mammals (see below), were 
shown to be less mobile and hence might be an explanation for its ability to block the access 
of transcription factors to binding sites in vitro [10]. Another possibility to change chromatin 
structure is based on the action of chromatin remodeling enzymes. Those molecular machines, 
often organized in protein complexes with several subunits, use ATP-hydrolysis to alter the 
histone-DNA interactions [11, 12]. This can lead to a variety of effects, such as repositioning 
of nucleosomes along the DNA, exchange, assembly or eviction of histones. Hence, the 
intrinsic inhibition of nucleosomes can be overcome and allow access of the transcription 
machinery to its target sites.  
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Figure 1-2: Principles that modulate chromatin structure and function. The nucleosome, which is composed 
of DNA (shown in blue) wrapped around the histone octamer (shown in purple) can be heavily modified. 
Posttranslational modifications (PTM) of histones are ‘written’, ‘erased’ and recognized by specific chromatin 
modifying factors. Histone variants (shown in green) can replace the conventional core histones (shown in 
purple) (modified, [8]) 
 
 
1.3 Dosage Compensation in C. elegans 
1.3.1 Composition of the C. elegans DCC 
Dosage compensation in C. elegans is brought about by a multi-protein complex 
called the dosage compensation complex (DCC). At least eight proteins are known to form 
the DCC and in contrast to the fly DCC non-coding RNAs are not known to be involved. 
Interestingly, several of those proteins (DPY-26, DPY-27 and DPY-28) show homologies to 
and even share (MIX-1) subunits of the condensin complex, an evolutionary conserved 
complex, which is needed for proper chromosome compaction and segregation during meiosis 
as well as during mitosis (Figure 1-3A and [13]). This homology suggests that also the DCC 
might act in a similar way: it could impose changes in chromatin structure, bringing different 
chromosomal compartments together and leading to their compaction, which consequently 
could reduce gene expression genome-wide [14, 15]. The DCC also includes subunits that are 
unique for this complex: SDC-1, SDC-2, SDC-3 and DPY-21. SDC-2 can be regarded as the 
key player in dosage compensation. Its expression decides whether the DCC is formed or not 
[16]. An X:A ratio of 1 (XX hermaphrodites) leads to repression, a ratio of 0.5 (XO males) to 
activation of expression of XOL-1, which in turn represses SDC-2 expression. SDC-2 is 
therefore only present in hermaphrodites. There it localizes specifically to the X 
chromosomes and not to the autosomes [16, 17].  Interestingly, SDC-2 acts independently, 
meaning it does not need any other DCC proteins for X chromosome binding [18]. The idea is 
that SDC-2 is the factor that initially distinguishes X from other chromosomes and 
subsequently promotes the assembly of the other DCC subunits. Because biochemical and 
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structural data are missing the mechanism of specific binding of SDC-2 remains unknown. 
Another protein also localizes to the X chromosomes, SDC-3, but it requires SDC-2, while all 
the other DCC subunits are dispensable [17]. Essential for dosage compensation (but not for 
its second role in sex determination) are two zinc finger domains of SDC-3. The presence of 
zinc fingers led to the assumption that SDC-3 might be able to bind to DNA via those 
domains and therefore be responsible for association of the DCC with the X chromosomes 
[17]. However, a direct involvement of SDC-3 and its zinc fingers in DNA binding has not 
been shown.  
 
1.3.2 Recruitment-and-spreading model  
The mechanism by which the DCC recognizes the X chromosomes is only poorly 
understood. Initially, huge X chromosomal fragments (1 - 5 Mbp) that were bound by the 
DCC in the native context were tested for their ability to recruit the DCC when detached from 
the X [19]. Regions were discovered that could indeed recruit the DCC autonomously, but 
some bound the DCC only weekly or not at all, despite the fact that they were able to tether 
the complex in the native X chromosomal environment. These findings lead to the 
‘recruitment-and-spreading’ model (Figure 1-3B): According to that the DCC binds to few 
recruitment sites dispersed along the X chromosomes and then spreads in cis from those sites 
to adjacent regions, which by themselves lack recruitment ability [19]. In a follow-up study, 
Meyer and colleagues dissected these regions further and found small, discrete recruitment 
sites, termed rex sites (recruitment element on the X), which occur widely spread on the X 
and share at least two distinct DNA sequence motifs. Mutations in those motifs disrupted the 
recruitment of the DCC in vivo. But surprisingly, the rex sites are not uniquely found on the X 
chromosome, neither are they enriched in comparison to the autosomes. However, the rex 
sites occur highly clustered on the X [20]. Taken together it could be shown that DNA 
sequence is indeed a determinant for X chromosome binding, but it seems that it is the 
clustering of motifs, which creates a DCC binding site. The model of the rex sites was further 
refined by high-resolution ChIP-on-chip mapping [21]. A 10 bp long consensus sequence 
encompassing the two previously proposed motifs was identified, which is again not 
exclusive to but more clustered on the X. Moreover, the DCC was found to be preferentially 
bound at the 5’-end of genes (promoters), leading to the idea that the complex represses 
transcription of the genes it binds, maybe by interfering with transcription initiation or with 
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polymerase-coupled spreading [21]. Accordingly, the complex would first recognize rex sites 
and then locally ‘hop’ to close-by promoters of active genes [22].  
However, recent findings obtained from another genome-wide analysis challenge this 
mode of action [23]: Unexpectedly, the proposed direct correlation between binding of the 
DCC and gene repression was not found. As a consequence, the authors propose an 
alternative model: The DCC is indeed recruited to rex sites, but then does not ‘hop’ and bind 
to 5’-end of genes where it represses transcription. It rather distributes to the newly identified 
dox sites (dependent on X sites), sites which are found preferentially in expressed genes but 
by themselves are not able to recruit the DCC. Because of the long distance that separates rex 
and dox sites (2 - 90 kbp), the DCC must somehow bring both kind of sites in physical 
vicinity, likely by altering the architecture of the X chromosome, for example by DNA 
looping. In that way the DCC would be able to spread and achieve gene repression over long 
distances and not locally at the genes it binds. Still, such a rearrangement of chromosomal 
domains has to be shown. Despite the progress that has been made, some important questions 
remain unanswered: First of all, it has not been shown which protein of the DCC is in fact 
binding to the consensus sequence. And secondly, since there are a lot of rex sites showing 
only weak similarity to the consensus sequence, it is clear that other determinants than DNA 
sequence must exist for forming a DCC binding site.   
 
 
 
Figure 1-3: Composition of the C. elegans DCC and the ‘recruitment-and-spreading’ model. (A) The 
condensin complex of C. elegans is specialized for compaction and segregation of mitotic and meiotic 
chromosomes, whereas the C. elegans DCC is specialized for dosage compensation. Proteins of both complexes 
are color-coded to show homologous proteins. (B) Multiple rex sites appear clustered on the X compared to 
autosomes and hence recruit the DCC specifically to both hermaphrodite X chromosomes. The DCC then 
spreads in cis to adjacent X regions that lack rex sites and establishes X-chromosome-wide repression. 
Alternatively, the DCC might distribute from rex to dox-sites bringing distant chromosomal regions together 
leading to gene repression over long distances (not shown in this figure) (modified, [24]). 
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1.3.3 Autosomal binding sites 
Genome-wide mapping revealed many more autosomal sites than previously judged 
from immunofluorescence studies [23]. The DCC binds to discrete, dispersed sites (mostly on 
promoters), but the typical consensus sequence and its clustering is lacking on the autosomes, 
demonstrating that the binding mode must differ from the one on the X chromosomes [23]. 
By depleting the SDC-2 subunit of the DCC, also autosomal gene expression was affected: In 
contrast to the X chromosomal genes, whose expression is decreased, the autosomal genes 
behave the other way round and get upregulated. Thus, the DCC functions not only on the X 
to adjust gene expression; it affects gene expression throughout the whole genome [23].  
So far only one autosomal site has been studied in detail, the her-1 gene. Since it 
promotes male development, it has to be shut down in hermaphrodites. This task is managed 
by the DCC, which binds to the promoter region of the her-1 gene and represses its 
transcription around 20 fold [25]. This of course raises the question how the DCC can bind to 
all those different sites (X vs. autosomal) and additionally evoke different effects (2-fold and 
20-fold down- and upregulation as well). It is speculated that the DPY-21 protein might be 
needed for fine-tuning transcription on the X. Its absence from the DCC on the her-1 region 
might unleash the full repressive potential of the DCC and reduce transcription around 20-
fold [22]. Whether these are common features important for all autosomal sites or just a 
special case for her-1 has to be seen.   
 
1.3.4 Mechanism of X chromosomal repression 
The mechanism by which the DCC represses gene activation is not known. The study 
by Ercan et al. [21] suggests that the DCC is targeted gene-by-gene and accumulates at the 
promoter region and transcriptional start sites. Consequently, the authors propose that the 
regulation by the DCC occurs at the level of transcription initiation [22], for example by 
preventing accessibility of the promoter to the transcription machinery. It is known that 
negative supercoils in the DNA can support transcription initiation [26]. The DCC could, like 
it was shown for the condensin complex [27], introduce positive supercoils (or eliminate 
negative supercoils) and that way hinder transcription initiation [22]. On the other hand, Jans 
et al. [23] proposed that the DCC might act over long distances, which requires chromosomal 
rearrangements. Gene repression would therefore be achieved not gene-by-gene, but globally, 
by specific condensation of the entire X chromosome. 
 
Introduction                                                                                                                               17 
1.4 Dosage compensation in mammals 
In contrast to fruit flies and the nematode C.elegans, dosage compensation in mammals 
does not involve a specialized protein complex, but is based on the combined action of the 
non-coding RNA Xist (X inactive specific transcript) and histone modifications [1, 28]. Such 
modifications influence the structure and state of chromatin, which consequently influences 
gene expression – in both directions: repression and activation as well. Especially post-
translational modifications on the histones, such as methylation, acetylation or 
ubiquitinylation, or exchange of histone variants, as well as chromatin remodeling machines 
and DNA methylation are known key players (see above and [7]). 
 
1.4.1 Selection of the inactive X chromosome  
Usually the selection of one of the two X chromosomes to become inactivated 
happens randomly early in development. After the choice has been made, expression of the 
non-coding Xist RNA is increased. The transcribed Xist RNA binds in cis and coats 
specifically that X chromosome from which it is expressed [29], leading to its inactivation 
[30, 31]. The second X chromosome, however, has to stay active and therefore Xist 
transcription from the active X (Xa) is prevented by the action of another non-coding RNA 
called Tsix [32]. Tsix is transcribed antisense to Xist on the active X; conversely Tsix is 
downregulated on the inactive X (Xi). Interestingly, the expression of Tsix, in contrast to 
Xist, declines over time, meaning that Tsix is not required to keep Xist downregulated on the 
Xa [32]. The question arises how Tsix is able to regulate Xist. There is evidence for a role of 
Tsix in changing the chromatin configuration at the Xist promoter. It could be shown that the 
chromatin structure at the promoter adopted a more open and transcriptionally permissive 
state in absence of Tsix [33]. In addition, in the absence of Tsix, several histone 
modifications, which are known to be related with transcriptional activation, were found to be 
accumulated at the promoter [34]. However, the machinery to do so was not identified. And it 
is also not solved, whether simply anti-sense transcription or the RNA itself triggers these 
changes. 
 
1.4.2 Mechanisms of X chromosome silencing 
The presence of Xist RNA is a mark for the inactive X chromosome. But how this 
labeling translates into silencing a chromosome is only poorly understood. In general it is 
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thought that Xist might serve as a scaffold to bring repressive complexes to the Xi. However, 
not much is known about the factors that interact with Xist. Interestingly, Xist RNA was 
shown to have distinct domains that exhibit different functions. For silencing so-called A-
repeats at the 5’-end are required, while coating is brought about by several domains 
dispersed over the entire RNA [35]. An interesting exception is the Xist RNA from humans, 
where the A-repeats carry out both functions, coating and silencing [36]. Still, silencing 
requires additional factors than just Xist. It was demonstrated that expression of Xist could 
not always induce silencing; it was dependent on the correct time and developmental stage, 
showing that the cellular context is critical for X inactivation. 
 Factors known to be involved in silencing are the polycomb repressive complexes 
PRC1 and PRC2. Both complexes were found on the Xi, where they set their characteristic 
histone modifications (H3K27me3 and H2AK119ub1) (Figure 1-4A). Surprisingly, both 
complexes and their marks were shown not to be essential for X inactivation [37, 38]. In 
addition, PRC1 and PRC2 were still to some extend found on the Xi, when the A-repeats of 
Xist (which are required for silencing) were deleted, demonstrating that the marks are not 
sufficient to trigger silencing. Several other repressive histone modifications are also 
associated with the Xi, while active marks like H3K4me and H4 acetylation are excluded 
[39]. Moreover, the histone variant macroH2A1 [40] gets incorporated, while H2A-Bbd is 
absent from the inactive X [41] and promoters of X-linked genes are methylated. DNA 
methylation is the modification that is in particular important for maintaining the X inactive 
through multiple rounds of cell divisions over the entire lifetime of the organism [42]. In 
summary, it became clear that it is not a single, but a whole series of different modifications 
with likely redundant functions that contribute to X chromosomal silencing (Figure 1-4A, C). 
It also seems likely that the responsible complexes identify the Xi via the Xist RNA, however 
nothing is known about the mechanism of their interaction.  
 Besides changes in chromatin state, X inactivation also involves a change in the 
nuclear organization (Figure 1-4). It was reported that the Xist RNA is involved in setting up 
a special silencing compartment, from which RNA-Polymerase II and the transcription 
machinery is excluded. During silencing X-linked genes move into the Xist-coated 
compartment, while genes that escape X inactivation are located outside it. Quite recently, 
two new players have been identified: SATB1 and SATB2 are known to be involved in the 
nuclear organization of chromosomal domains during T-cell development [43]. Now it was 
shown that Xist’s restricted ability to induce silencing outside a certain developmental context 
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is dependent and can be overcome by the re-expression of those proteins [44], which links 
silencing and chromosome organization.   
  The fact that some X-linked genes are able to escape inactivation is mechanistically 
interesting. Besides the genes in the pseudoautosomal region, which have their counterparts 
on the male Y chromosome and therefore do not have to be compensated, there are reports 
that about 15% of human X-linked genes are escapees [45]. A more recent study, however, 
claimed that inactivation is almost complete [46]. An interesting explanation for how 
escaping is achieved is based on the LINE hypothesis: LINE-1 elements (long interspersed 
nuclear element) occur with different densities on the X and on the autosomes. Since the 
density on the X chromosomes is higher LINE-1 elements are thought to facilitate the 
spreading of Xist RNA specifically along the Xi and not on the autosomes (Figure 1-4); they 
consequently help to recruit genes into the silencing compartment, which leads to their 
inactivation [47]. Accordingly, having a low LINE-1 density would accordingly prevent 
genes from being silenced [48, 49].   
 
 
 
Figure 1-4: Mechanism of X inactivation in mammals. (A) Combined IF and RNA FISH on two days 
differentiated female mouse ES cells revealed that the Xist-coated transcriptionally silent compartment is 
enriched for marks such as H3K27me3. (B) Coating of the X chromosome with Xist RNA leads to formation of 
a transcriptionally silent compartment, which might require the matrix-associated proteins SATB1/2. Genes that 
are silenced are recruited into, whereas those that escape silencing are excluded from this compartment. (C) The 
Xist RNA spreads along the X chromosome, which might be facilitated by LINE-1 elements, to finally coat the 
entire X. Various histone modifications and incorporation of histone variants transform the Xist-coated X into an 
inactive chromatin state (modified, [28, 50]). 
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1.5 Dosage compensation in Drosophila melanogaster 
1.5.1 Composition of the Drosophila melanogaster DCC 
In the fruit fly dosage compensation is mediated by a large ribonucleoprotein complex, 
the dosage compensation complex (DCC) or alternatively called MSL complex (Figure 1-5). 
It consists of at least five proteins, which are essential for male but not for female viability, 
and were for that reason termed male-specific lethal proteins (MSL). For two of the MSL 
proteins, the histone acetyltransferase MOF and the helicase MLE, enzymatic activities were 
assigned, which are also important for non-dosage compensation functions [51]. The other 
MSL proteins (MSL2, MSL1 and MSL3) seem to be rather structural components of the DCC 
[52].  
Several other associated proteins, which have additional, more general functions not 
only related to dosage compensation, were identified, for example the JIL1 kinase [53, 54] or 
the supercoiling factor SCF [55]. But how they mechanistically contribute to dosage 
compensation is not known. Besides protein subunits, the DCC also incorporates non-coding 
RNAs, roX1 and roX2 (RNA on the X). The two RNAs differ extremely in size and sequence 
[56]; nonetheless both are able to substitute for one another, suggesting that they have 
redundant functions [57]. Their contacts with the DCC occurs via MSL3, MOF or MLE – 
MSL proteins for which RNA binding activity has been shown in vitro.  
 
 
Figure 1-5: Schematic representation of the components of the DCC. The DCC or MSL complex is 
composed of five male-specific lethal proteins and two non-coding RNAs roX1 and roX2. Associated factors, 
like the super-coiling factor (SCF), the JIL1 kinase and nucleoporines (not shown in the scheme) and maybe 
other not yet discovered factors (X) are discussed to be involved in dosage compensation. 
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All the MSL proteins are also present in females, but since the expression of the key 
player MSL2 is inhibited by the regulatory protein SXL (sex lethal) in females the DCC 
assembles exclusively in the male sex [58, 59]. The DCC then covers almost the entire single 
male X chromosome leading to specific acetylation of histone H4 at lysine 16 [60], which is 
thought to be at least in part responsible for increased transcription of X-linked genes.   
 
1.5.2 Mechanism of two-fold activation 
It is of major interest to understand how the action of MOF in dosage compensation, 
that is the specific acetylation of H4K16, regulates transcription. The prevailing and most 
intuitive model suggests that MOF and the DCC work as direct activators of gene expression. 
Another idea termed ‘inverse dosage effect’ is that the DCC functions to down-regulate 
autosomal genes rather than to activate the X-linked genes [61]. This model is based on the 
idea that global regulators, such as MOF, which is also a general regulator in females [62, 
63], would be removed from the autosomes and tethered to the X chromosome by the DCC. 
The result would be an accumulation of global activators on the X, which consequently would 
reduce transcription from the autosomes (Figure 1-6 and [64]). However, it was shown that 
the loss of DCC targeting directly correlated with reduced transcription of X-linked genes, 
while no effect was observed for the autosomal genes, which strongly favors the role of the 
DCC as a direct activator [65, 66]. 
 
 
Figure 1-6: Different models of dosage compensation in flies. In model A the DCC directly activates gene 
expression on the male X chromosome leading to equal levels of gene products in males and females. In model 
B global activators are distributed equally on the X and the autosomes in females. By contrast, in males global 
activators are removed from the autosomes and accumulated on the X chromosome by the DCC (modified, 
[64]).  
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In general, gene activation is known to be linked to histone acetylation. This histone 
mark by itself is able to decondense chromatin structure, leading to a more permissive state 
for interacting factors [67]. The organization of higher-order chromatin, however, is also 
regulated by additional factors, such as chromatin remodeling complexes. For example, 
interfering with the function of ISWI, an ATPase found in several chromatin remodeling 
complexes of Drosophila, caused decondensation of the male X chromosome in vivo, which 
is accompanied by reduced levels of linker histone H1 that is incorporated into chromatin [68, 
69]. On the other hand, acetylation of H4K16 antagonizes ISWI function in vivo and in vitro 
and therefore it is thought that H4K16ac is important to counteract the compaction of 
chromatin caused by ISWI [70]. With regards to X-linked genes H4K16ac levels are 
relatively low at promoters compared to 3’-end of genes. Also the binding of the DCC is 
preferred at 3’-ends, as shown by genome-wide mapping [71, 72]. For that reason it was 
proposed that gene expression is regulated at the level of facilitating transcription elongation 
and not by increasing the accessibility of promoters [71-73].  
Still, it remains unclear how the H4K16ac mark translates into a precise two-fold 
activation. First insights into the mechanism came from biochemical analysis. Recombinant 
MOF protein was able to specifically acetylate H4K16 in nucleosomal arrays in vitro. As a 
consequence the chromatin-mediated repression of transcription could indeed be overcome 
but transcription was boosted far more than two-fold [74]. When MOF was in a sub-complex 
with MSL1 and MSL3, the substrate-specificity was improved [75]. In addition the histone 
acetyltransferase activity was even further increased, indicating that for MOF’s full function 
the other MSL proteins are required. Interestingly, the roX RNAs are not involved in 
acetylation in vitro [75], suggesting a role for the RNAs rather in complex assembly or 
targeting but not in activation. Nevertheless, for achieving two-fold activation, a feedback 
mechanism would be required, perhaps by an additional repressive function within the DCC. 
Clues for such a repressive function could come from dissecting other MOF containing 
complexes. In fact MOF was shown to be present not only in male but also in female flies and 
even in human cells [62, 63]. Biochemical purifications show that MOF is also present 
outside the DCC in other complexes ([63] and M. Prestel, P. Becker lab, manuscript 
submitted). Moreover, it was postulated that the two distinct MOF-complexes (in flies) also 
exhibit different binding patterns: While the classical MOF complex, the DCC, is found 
preferentially at the 3’-end of genes on the X, an alternative MOF complex prefers binding to 
promoters of autosomal genes [76]. This indicates that the two MOF complexes might also 
mechanistically function in different ways. By comparing their composition and their 
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operating principle one might gain more insight into how gene activation by MOF can be 
restricted to two-fold.   
 
1.5.3 Principles of X chromosome targeting  
The mechanism by which the DCC selects specifically the X and not the other 
chromosomes is not well understood. Genome-wide high-resolution mapping revealed that 
the DCC does not bind within promoter or enhancer sequences, but is localized to the coding 
sequence of active genes (Figure 1-8A), indicating that the complex acts rather at the level of 
transcriptional elongation than initiation [71, 72]. The similar binding patterns of the DCC 
and of a histone modification known to be involved in active transcription, the trimethylation 
of H3K36, and the requirement of this modification for recruitment of target genes [77, 78], 
led to the idea that this histone modification might serve for the DCC as a recognition feature. 
Since almost all active genes are compensated [4], an active mark would indeed be a simple 
signal for the DCC to find its target genes. On the other hand this recognition mark is not 
specific for the X chromosome, and consequently, other determinants must be involved.  
Early studies on dosage compensation favored the idea of an involvement of DNA 
sequences. Normally, the DCC assembles only in the male sex, but if the key player MSL2 is 
ectopically expressed in females, then the DCC forms also there and binds to the X 
chromosomes [59]. All the information necessary for binding must therefore be represented 
within the X chromosomes, leading to the idea of specific DNA sequences that are unique for 
the X and that serve as recognition sites for the DCC. Hundreds of sites where the complete 
DCC is bound can be visualized (but in low resolution) by immunostaining of giant polytene 
chromosomes from the salivary gland of larvae. The number of sites is dramatically reduced 
to 30 - 50 when MSL3, MLE or MOF are absent (Figure 1-7), showing that a subcomplex 
consisting of only MSL2 and MSL1 is sufficient for recognizing X chromosome binding sites 
[59, 79, 80]. These sites where termed ‘chromosome entry sites’ (CES) and were thought to 
be the initial recruitment sites for the MSL2-MSL1 subcomplex. Subsequent to this 
recruitment the association of the other MSLs and of the roX RNAs leads to the formation of 
the full complex, which spreads to neighboring chromosomal regions and finally covers all 
secondary sites on the entire X [81].  
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Figure 1-7: Hierarchy of DCC binding sites. Polytene chromosomes from Drosophila melanogaster larvae 
stained with MSL1 antibodies show binding of the DCC to a defined pattern of sites. (A) Partial or nonfunctional 
complexes bind to a subset of sites, with the MSL2-MSL1 subcomplex being the minimal requirement for 
binding to HAS. (B) Different MSL2 expression constructs (NOPU and SXB1-2) give rise to decreasing levels 
of MSL2 in females, which leads to decreasing levels of complex and to the same binding pattern as in (A), 
suggesting different affinities for the binding sites (modified, [82]).   
 
 
The entry site model was based on the characterization of two CES within the roX1 
and roX2 genes. Indeed, when the roX genes were inserted into autosomes, the DCC was 
bound to those insertion sites and moreover spreading of the DCC to neighboring, secondary 
sites on the autosomes was observed [83, 84]. However, by analyzing more binding sites it 
became clear that also X chromosomal sites that do not have the DCC bound (which are 
consequently not CES) could recruit the complex when inserted into autosomes and that the 
other way round, parts of the autosomes when translocated to the X to a nearby entry site 
could not attract the DCC [85, 86]. These findings led to a refinement of the characteristics of 
binding sites. By continuously reducing the level of the complex in vivo it was shown that 
fewer and fewer sites were bound by the DCC, leading to the idea of a hierarchy of binding 
sites [82, 85, 87]. According to this affinity model (Figure 1-7), the DCC or a subcomplex 
binds first to sites with highest affinity and as the levels of complex increase, sites with 
middle and low affinity get successively bound. In the absence of the full complex, the partial 
MSL2-MSL1 subcomplex can still bind to the X, but only to the high affinity sites, whereas 
the sites with lower affinity are bound when the complex is fully assembled and its 
concentration increases [64, 82]. However, some X-chromosomal sites that are strongly 
bound by the DCC were not able to recruit the complex when inserted on an autosome [88]. 
In these cases it is possible that the strong binding on the X is not due to the fact that these 
sites are real high affinity sites, but instead are low affinity sites that profit from high 
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concentrations of the DCC on nearby high affinity sites. A consequence of the affinity-based 
targeting is that at a certain concentration of complex (achieved by overexpression of MSL 
proteins) also non-target sites, such as autosomal sites get bound, showing that the level of 
MSL proteins and roX RNAs has to be tightly regulated to restrict the action of the DCC on 
the X chromosome [87, 89, 90].  
Recent data proposed an additional feature required for targeting, namely the 
involvement of transcription. When high affinity sites from the X were inserted into 
autosomes, the DCC could be recruited, but only when either transcription through these 
inserted genes was allowed or when the insertion site was inserted as multiple copies. This 
suggests that transcription is not absolutely required, but it facilitates the recruitment by 
increasing the accessibility to a binding site (Figure 1-8 and [91]).  
 
 
Figure 1-8: Principles of X chromosome targeting by the Drosophila melanogaster DCC. (A) Genome-wide 
high-resolution mapping of DCC binding sites on the male X chromosome. Targeting might be achieved by the 
following models: (B) The DCC recognizes specific DNA sequences (HAS), which carry a consensus motif (e.g. 
MRE), based on binding affinity. (C) Factors associated with active transcription, e.g. RNA Polymerase II or 
H3K36me3 are required to expose specific binding sites. (D) A two-step model: The DCC initially recognizes 
primary target elements and then spreads in cis into neighboring regions independent of sequence, instead using 
the transcription machinery (modified, [3]).    
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1.5.4 High affinity sites and DNA recruitment elements  
The concept of a hierarchy of binding sites raises the question of what might be the 
determinants and common features characteristic for high affinity sites (HAS). First 
description came from in vivo studies of single HAS. Well-characterized binding sites are the 
nucleosome-free DNAse hypersensitive (DHS) sites within the roX genes [83, 84], the 18D 
HAS [86] and  the Smr and Tao-1 gene [82]. Common for all those sites is their ability to 
recruit the DCC when they are inserted into autosomes, which suggests that DNA sequence 
could be a major prerequisite for defining a HAS. Nevertheless, the relatively large size 
(about 200 bp) and the small number of identified sites made it impossible to derive a 
common DNA sequence motif, indicating that there might be different classes of binding sites 
[82, 86]. The two roX DHS anyway seem to be rather atypical HAS, because they require the 
MLE helicase and one of the two roX RNAs for recruitment of the complex [83, 84], whereas 
the other high affinity sites can be bound in the absence of roX RNAs [82, 86]. Also 
transcription seems not to be a feature of HAS, since some sites, e.g. the 18D HAS, are not 
transcribed at all [86], while others, e.g. the roX genes, indeed produce transcripts (the roX 
RNAs), on the other hand the transcription per se from roX genes is not needed for DCC 
recruitment to the roX HAS [57, 83].  
The dissection of HAS in more detail allowed to further narrow down the HAS to 
smaller X chromosomal fragments, so-called DCC binding fragments (DBF), which are 
sufficient to recruit the DCC in vivo. From the around 15 DBFs it was possible to determine 
several GA-rich DNA elements, which appear clustered within HAS [82]. Nevertheless, the 
still relatively large size of the DBFs (several thousand kilobases) complicated further 
refinements of potential consensus sequences.  
In order to identify minimal binding elements within the DBFs that are recruiting the 
DCC, a reporter gene assay was developed (Figure 1-9 and [92]). In this assay several 
candidate binding sites derived from the DBFs were cloned in front of a minimal promoter 
driving transcription of a luciferase reporter gene. The plasmid is transfected into male 
Drosophila melanogaster SL2 cells together with a plasmid that allows expression of an 
MSL2-VP16 fusion protein. Upon binding of the MSL2 fusion protein to the potential 
binding element, the VP16 activation domain leads to the expression of the luciferase reporter 
gene. Because of the VP16 activation domain transcription is even boosted, allowing the 
detection of also weak protein-DNA interactions. The screening identified several minimal 
targeting elements, but sharing only little similarity and with no obvious consensus sequence. 
Among others, a small 40 bp sequence derived from DBF12 within the Smr gene, the so-
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called DBF12-L15 element was identified as a recruitment site. It contains a GA repeat and 
interestingly, mutating the GA motif to a stretch of thymines (DBF12-L18) destroyed the 
function as a DCC recruitment site (Figure 1-9). Furthermore when trimerized and inserted 
into autosomes it created one of the strongest recruitment sites seen so far [92]. Consequently, 
it is thought that DCC binding sites might be composed of clusters of several degenerative 
sequence motifs.  
 
 
Figure 1-9: Reporter gene assay to identify DCC binding sites. MSL2-VP16 activator construct and a 
luciferase reporter gene, which carries a candidate binding site, are transfected into male Drosophila 
melanogaster SL2 cells. Upon binding of MSL2-VP16 to the binding site expression of the reporter gene is 
activated. Binding of MSL2-VP16 might either be direct or indirect (via an unknown factor X) and might require 
the DCC subunits. Among others a 40 bp DNA sequence (DBF12-L15) was identified to be the minimal element 
necessary for MSL2-VP16-mediated reporter gene activation. An DNA element (DBF12-L18) carrying 
mutations in the GA-rich sequence abolished reporter gene activation.  
 
 
In order to facilitate the discovery of common features, the high-resolution analysis 
were recently extended to map exclusively HAS [93, 94]. To ensure that binding is restricted 
preferentially to HAS, the complex concentration in SL2 cells was reduced by applying RNAi 
against individual MSL proteins, combined with less stringent crosslinking conditions [94]. 
Alternatively, MSL3 mutant flies were used, where the lack of MSL3 allows only the 
formation of a subcomplex consisting of MSL2-MSL1 and roX-bound MLE [93]. Both 
strategies led to the identification of a subset of around 150 binding sites, which were still 
bound under the mentioned conditions and therefore meet the criteria of a HAS. By using 
bioinformatic analysis, again a GA-rich motif, which is similar to the one discovered in the 
reporter gene screen [92], was found to be common in HAS and was proposed as a MSL 
recognition element (MRE). However, the MRE was only slightly enriched on the X 
chromosome compared to autosomes, and also not every MRE found on the X was bound by 
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the DCC [93, 94]. This indicates that such a motif alone might not be sufficient to create a 
HAS. Interestingly, the identified motif occurs on sequences that are depleted of histone H3, 
indicating that initial DCC binding requires a naked, histone-free DNA template [93, 94].    
 
1.5.5 The MSL2-MSL1 targeting machinery 
Not only are the requirements for a HAS not fully understood, but in addition the 
factors that recognize such binding sites are not clearly identified. Not all subunits of the 
DCC are needed for initial recruitment. The roX RNAs seem to be dispensable since the 
overexpression of MSL proteins can overcome the lack of roX RNAs and consequently 
successful localization of the DCC to the X and acetylation of H4K16 was observed [89]. On 
the other hand the absence of roX RNAs led to increased DCC binding to autosomes and to 
the chromocenter, showing that roX RNAs are needed to ensure proper targeting [89]. 
However, it is clear that the targeting domains reside within the protein components of the 
DCC. The DCC subunits MSL3, MOF and MLE were shown to be not required; a 
subcomplex of MSL2 and MSL1 is sufficient to recognize the HAS on the X chromosome. 
Binding to the HAS depends on both proteins, the individual subunits by themselves are not 
able to bind to the X [80]. One exception is known for the roX genes, where MSL2 does not 
need any other MSL proteins and is alone sufficient to drive the transcription of roX RNA 
[95]. How this function outside of the DCC is achieved is unknown, but the mechanism seems 
not to rely on autonomous binding of MSL2 to the roX HAS, since deleting it had no effect 
on roX transcription [95]. The MSL2-MSL1 subcomplex and the HAS do not only ensure the 
proper selection of the X chromosome, they were recently found to lead to a clustering of 
HAS, which in turn sets up a male-specific X chromosome conformation [96]. An 
involvement of nucleoporines, which were previously thought to act in dosage compensation 
[63], could be excluded.      
It is also mysterious how the direct contact to the X chromosome is achieved, whether 
only one protein establishes contacts to DNA or whether both proteins together form a 
common binding domain. Neither for MSL1 nor MSL2 a typical DNA binding domain is 
known or predicted (Figure 1-10). MSL1 is composed of several domains, which mediate the 
interactions with the other MSL proteins, showing its central role in complex assembly [97]: 
The coiled-coil domain mediates interaction with MSL2, the PEHE domain with MOF and 
the C-terminal part with MSL3 [75]. The short N-terminal region was suggested to be 
involved in X chromosome association in vivo: When the first 84 aa were deleted, MSL1 
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could still interact with MSL2, but MSL1 was not recruited anymore to the X chromosome, 
but strikingly, MSL2 was still bound to the X [97, 98]. The domain within MSL2 that could 
be responsible for X chromosome binding is not known. The N-terminal RING finger was 
shown in yeast two-hybrid assays to mediate the interaction with MSL1 [79], whereas a 
conserved CXC domain has no described function yet, and a sequence rich in prolines and 
basic amino acids (Pro/Bas patch) is thought to be important for incorporation of roX RNA by 
an unknown principle [99]. Taken together, these findings strongly favor the idea that indeed 
both proteins are co-dependent for, but on the other hand it is the MSL2 protein that mediates 
the interaction with the X chromosome. Such a contact to DNA might be based either on 
typical protein-DNA contacts characterized by an equilibrium between DNA-bound and 
unbound state, or involve a stable, topological ring formation around the X chromosomal 
DNA, as suggested from the very slow turnover of MSL2 measured by photobleaching 
experiments [100]. Whether the interactions are direct or involve an unknown additional 
factor has to be addressed, as well as the biochemical proof of the MSL interactions with 
DNA.  
 
Figure 1-10: Components of the DCC. (A)-(E): The protein subunits, their domain organization and function 
of the individual domains are shown. (F)-(G): The two non-coding roX RNAs and conserved roX box elements 
are depicted in red and blue (inverse roX box) (modified, [52]). 
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1.6 Protein-DNA interactions  
The selection of the correct DNA binding site from the vast amount of other binding 
sites in the genome is a mechanistically challenging task for all DNA binding proteins. For 
some aspects, like the organization of DNA by chromosomal proteins, it is, however, not 
desirable to have a special target sequence, but instead the protein should bind to DNA with 
minimal sequence specificity [101]. To manage the problem of specificity, numerous different 
DNA binding domains have evolved and are not only found in the family of transcription 
factors, but also in proteins that mediate recombination or DNA cleavage [102]. In the 
following section basic principles of DNA recognition are illustrated by examples.  
 
1.6.1 DNA binding domains 
One of the most frequently found motifs is the helix-turn-helix (HTH) structure, 
occurring for example in the  repressor (Figure 1-11A),  Cro protein or in the E.coli CAP 
protein [103]. Two helices, which vary in length between the individual family members) are 
linked by a tight bend, whereby the second helix inserts into the major groove of the DNA 
duplex, where both base and DNA backbone contacts are formed [104, 105]. The orientation 
and position of the second helix in the major groove varies drastically within the HTH family, 
leading to different ways of docking of the HTH against the DNA and establishment of 
different interactions (Figure 1-12A). Not only helix 2 and 3 make contacts with the major 
groove, but also regions outside the HTH motif are needed for binding, e.g. the flexible linker 
arm at the N-terminus of the HTH motif of the  repressor [106]. It is therefore not surprising 
that the HTH motif is not able to function by itself and is always a part of a larger DNA 
binding domain [103].  
The classes of basic region-leucine zipper (bZIP, Figure 1-11B) and helix-loop-helix 
(HLH) proteins are characterized by two distinct subdomains: A basic region (rich in 
arginines and lysines), which forms contacts with the DNA and a dimerization region, either 
an HLH motif or a leucine zipper [107-109]. The leucine zipper shows repeats of leucines 
over 30 - 40 residues and forms two parallel helices in a coiled-coil arrangement [108]. 
Different bZIP proteins are able to form also heterodimers via their leucine zipper helices. 
Such mixed dimers, for example the proteins Fos and Jun form the transcription factor AP-1, 
expand the repertoire of target sequences and allows regulating protein function [110]. By 
contrast, HLH proteins have a different dimerization interface composed of two helices 
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separated by a loop [109]. For both protein families the interaction with the DNA is achieved 
by the basic region. It adopts a long helical structure, which inserts into the major groove. 
This helical arrangement is only structured in the presence of DNA, otherwise it is disordered 
[111]. Interestingly, the basic region of GCN4 does not need the classical leucine zipper 
motif, also a simple disulfide bound between the two helices is sufficient to allow 
dimerization and consequently binding of the specific target sequence is achieved [111].  
Besides the major groove also the minor groove can serve for interaction, whereby 
sufficient distortion of DNA is a prerequisite (Figure 1-11C), which is at first energetic costly 
but can be compensated by the favorable contacts that are achieved [102]. Examples are 
found in the family of lacI proteins, e.g. the lac repressor or the purine repressor dimer 
(PurR). Each PuR monomer forms two separate binding modules (Figure 1-11C): A classical 
HTH motif to contact the bases in the major groove and a two-turn hinge helix to contact the 
bases in the minor groove [112]. The hinge helices associate via hydrophobic interactions and 
lead to unwinding and bending of the DNA away from the protein, opening the minor groove 
to enable the contact between side chains of the hinge helix pair and bases in the minor 
groove. Hydrophobic side chains (leucines) of the hinge helices assist in keeping the 45° kink 
in the DNA open. An even more extreme example of promoting DNA distortion is the TATA 
binding protein (TBP). Its huge ten-stranded -sheet induces drastic unwinding and bending, 
which allows the concave surface to interact with bases in the now opened minor groove [113, 
114]. Similar to PurA, the distortion is mainly due to the intercalating hydrophobic side 
chains (phenylalanine) into the DNA.  
Other major structural motifs – the zinc finger proteins – can have additional 
functions, which are not only restricted to DNA binding. Examples and their mode of action 
are discussed below in more detail (Figure 1-11D, E and Figure 1-13).  
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Figure 1-11: Representative examples of different DNA binding folds. (A) Helix-turn-helix structure (in red) 
of the bacterial  repressor. (B) Basic region-leucine zipper of GCN4. (C) LacI member: purine repressor dimer. 
(D) Cys2His2-type zinc finger (coordinated zinc ion in green) of zif268 transcription factor. (E) Two Cys2Cys2-
type zinc fingers (coordinated zinc ion in green) in each monomer of the DNA binding domain of the nuclear 
receptor heterodimer RXR (in blue) and RAR (in yellow) (modified, [102]). 
 
1.6.2 Principles of DNA recognition 
The contacts with the DNA bases are central for site-specific binding. As seen above, 
these contacts occur mainly with the bases of the major groove, which is not only larger, but 
offers also more potential sites for hydrogen bonding than the minor groove. In the minor 
groove, the combinations of hydrogen bond donors and acceptors are quite limited, since A-T 
pair is similar to T-A and G-C is similar to C-G. However, it is impossible to derive a simple 
recognition code [115]; especially when one considers the different ways of how an -helix 
can be positioned in the major groove (Figure 1-12A), the flexibility of many side-chains and 
the modest energetic costs of small DNA distortions. Nevertheless, some recurring themes of 
recognition can be observed [115]: The majority of sequence-specific interactions are thought 
to come from hydrogen bonding. In contrast to a single hydrogen bond, bidentate interactions, 
in which a single side chain (e.g. of arginine) establishes two hydrogen bonds (e.g. with the 
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guanine base), contribute to a higher specificity (Figure 1-12B, C). Since guanine is the only 
base in the major groove that contains two hydrogen bond acceptors, a substitution by any 
base would reduce DNA binding affinity. Other pairings like glutamine or asparagine with 
adenine and lysine with guanine are also found to be important for site-specific recognition 
(Figure 1-12C and [116]). Van der Waals interactions (e.g. between thymine methyl group 
and protein side-chains) play a minor role, since they lack a directional requirement (Figure 
1-12B and [102]). The DNA backbone itself does not contain sequence information; 
nevertheless the contacts with the DNA backbone (achieved by basic or neutral hydrogen-
bonding side chain that contact phosphodiester oxygens) also contribute to sequence-
specificity, mainly by positioning the protein in order to allow the establishment of the correct 
hydrogen bonds [103].  
Contacting the DNA backbone and the minor groove are also main features of 
sequence-independent DNA binding proteins. Those proteins, e.g. the chromosomal protein 
HMG-D or the archaeal DNA chaperone Sac7d, have to avoid sequence-specific contacts and 
instead establish sequence-neutral interactions with invariant DNA positions, such as the 
sugar-phosphate backbone, to obtain affinity without specificity [117, 118]. Especially water 
molecules are involved in allowing variation in the recognized sequence, since they can 
cushion the interface, allowing electrostatic interactions to dominate. Moreover, key residues 
(see above) can be bridged by water molecules (Figure 1-12D), so that space is filled up and 
additional hydrogen bonds are offered, which add stability but not specificity [101].  
 
 
 
Figure 1-12: Principles of protein-DNA interactions. (A) Different orientations of -helices within the helix-
turn-helix family inserted in the major groove of DNA. (B)-(D) Details of protein-DNA contacts. (B) Bidentate 
hydrogen bonds between arginine side chain and guanine base (yellow dashed lines). Hydrophobic contacts 
between amino acid side chains to a thymine methyl group (green dashed line). (C) Glutamine side chain forms 
bidentate contacts with adenine base and additional contacts to another glutamine side chain, which in turn 
contacts a phosphate group of the DNA backbone ( repressor-DNA complex). (D) Water-mediated hydrogen 
bonds within the helix-turn-helix structure of the Trp repressor bound to DNA (modified, [102]).    
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1.6.3 Zinc finger proteins  
Zinc finger structures are quite common in higher organisms, with more than 15000 
classical zinc finger domains predicted in around 1000 human proteins and more than 20 
additional related classes [119, 120]. The only common property of all those very diverse 
structures is simply that their protein fold is maintained by coordinating zinc ions via cysteine 
or histidine residues (Figure 1-13). The classical Cys2His2-type zinc finger was first 
discovered in TFIIIA [121, 122] and crystal structures of related transcription factors, such as 
zif268, revealed that it is the most simple zinc finger: It is composed of a short -helix, two 
antiparallel -sheets and a zinc ion coordinated by two histidines (in the -helix) and two 
cysteines (near the turn in the -sheet) (Figure 1-11D and [123]). Such a motif occurs mostly 
as multiple copies within a protein and uses the -helix to insert into the major groove of the 
DNA, whereupon the next zinc finger wraps around the double helix and makes another DNA 
contact [124]. The superfamily of nuclear hormone receptors binds their target DNA sequence 
as homo- or heterodimers. The DNA binding domain of one monomer is composed of a pair 
of zinc finger motifs [125]. Each motif coordinates a zinc ion by 4 cysteine residues 
(Cys2Cys2-type) ensuring the formation of a peptide loop between two of the cysteines and an 
adjacent -helix (Figure 1-11E). The first helix fits into the major grove to establish base 
contacts, while the second helix provides on the one hand phosphate contacts with the DNA 
backbone and on the other hand the dimerization interface [126].  
 
 
Figure 1-13: Topology and structure of different zinc finger domains. -sheets are represented as black or 
light blue arrows, -helices as black boxes or red helices and coordinated zinc ions as blue spheres. Details are 
found in the text (modified, [127]). 
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Besides those two mentioned zinc fingers, also other various cysteine or histidine-rich 
motifs exist, varying drastically in sequence, clustering and spacing (Figure 1-13). As a 
consequence, it is impossible to predict their structure or function and their role in DNA 
binding has to be shown experimentally. In fact, several zinc finger structures, including the 
classical Cys2His2-type, have additional functions in mediating protein-protein [127, 128] and 
protein-RNA interactions [129, 130]. The TFIIIA transcription factor not only recognizes the 
5S rRNA gene, where it regulates transcription, but also the 5S rRNA to stabilize the RNA 
until usage for ribosome assembly [131, 132]. All but the fourth and sixth Cys2His2-type zinc 
finger of TFIIIA directly interact with DNA, whereas zinc finger four and six present non-
DNA binding spacers to properly position the DNA binding zinc fingers (Figure 1-14A and 
[124, 133]. By contrast binding to the 5S rRNA requires direct contacts of the zinc finger four 
and six, where they recognize elements in the loop region of the RNA using the N-terminal 
ends of their -helices (Figure 1-14B and [134]). The location of the -helix and the base 
contacts that are made with RNA differ from those that are made with DNA by the other 
DNA binding zinc fingers of TFIIIA, however, some crucial base contacts are found in both 
RNA and DNA [124, 134]. Interestingly, the zinc finger five is involved in both DNA and 
RNA binding (Figure 1-14C, D). It binds DNA in the typical Cys2His2 zinc finger fashion 
using the side-chains of the -helix to establish base and DNA backbone contacts in the major 
groove (Figure 1-14C and [124]). Binding to the equivalent RNA sequence, however, does 
not involve base contacts, instead contacts of the side chains of the -helix with the backbone 
of the major groove of the RNA are established, which, notably, are the same found in 
complex with DNA (Figure 1-14D and [134]). Hence, the classical zinc finger five recognizes 
both DNA and RNA and thereby makes use of overlapping sets of side chains to contact 
nucleic acids. It has to be noted that the principles by which proteins recognize DNA or RNA 
are influenced by fundamental differences in the structure of the nucleic acids. Most 
importantly, the major groove of the RNA is too narrow to accommodate a -helix and in 
contrast to DNA, the tertiary structure of RNA is another significant factor that contributes to 
the formation of protein-RNA complexes.    
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Figure 1-14: Comparison of DNA and RNA binding of the zinc finger protein TFIIIA. (A) All classical 
Cys2His2-type zinc fingers of TFIIIA, except zinc finger 4 and 6, which are needed for proper spacing, 
participate in direct interactions with specific DNA sequences of the 5S rRNA promoter (Box C, IE and Box A). 
(B) In addition to zinc finger 5, also zinc finger 4 and 6 recognize elements of the 5S rRNA (loop E, helix V and 
loop A). Details of contacts of zinc finger 5 (grey cartoon trace), either with DNA of the 5S rRNA gene (C) or 
with 5S rRNA (D). In the DNA-bound state, the -helix (depicted as grey helix) inserts into the major groove of 
the DNA and establishes hydrogen bonds between amino acids side chains and bases of the DNA (C). In the 
RNA-bound state the side chains of the -helix do not contact the bases of the RNA but form contacts to 
phosphate groups of the RNA backbone (D). Color code: Nitrogen in blue, oxygen in red, carbon in yellow, 
sulfur in orange and phosphorus atoms in magenta. Coordinated zinc ions as grey spheres (modified, [130]).  
  
 
Zinc finger domains can also function as protein recognition motifs [127, 128]. The 
occurrence of classical zinc fingers as multiple copies or arrays allows the assignment of 
different functions for the single zinc fingers. It was shown for the Ikaros family of 
transcription factors that one cluster consisting of several zinc fingers overtakes the function 
of DNA binding, while the other cluster mediates interaction with other zinc finger domains 
either of the same or of a different family member, leading to high affinity DNA binding 
[135, 136]. Other examples are known, where DNA recognition and protein-interaction 
function are even harbored within the same zinc finger: The N-terminal classical zinc finger 
of GATA-1 uses distinct surfaces to bind simultaneously to DNA and to a zinc finger of its 
interaction partner FOG-1 (‘Friend of GATA-1’), whose protein interaction surface, by 
contrast, overlaps with the classical DNA binding surface (Figure 1-15A and [137]).  Other 
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zinc finger structures, like the LIM, RING and PHD domains function primarily as protein-
protein interaction surfaces (Figure 1-13 and [127]). LIM domains are composed of two 
sequential zinc-binding modules that are packed against each other to form a single domain. 
Within this family not only cysteine and histidine, but also aspartate and glutamate residues 
are found to coordinate more than one zinc ions; with differing length of the loops between 
the zinc ions [138]. As seen for the LMO4 and the ldb1 protein, four of the eight -sheets of 
the two tandem LIM domains (LIM1 and LIM2) of LMO4 are used to pair with -sheets of 
the LIM interaction domain of ldb1, leading either to primarily hydrophobic (first LIM 
domain) or to a mixture of electrostatic and hydrophobic interactions as seen in the second 
LIM domain (Figure 1-15B and [139]).  
 
 
Figure 1-15: Protein-protein interfaces. (A) Interaction of the N-terminal classical GATA-1 zinc finger (in 
light blue) in with the FOG-1 zinc finger (in red). The DNA binding surface of the GATA-1 zinc finger (contacts 
depicted in yellow) does not overlap with its FOG-1 interaction surface (contacts depicted in green, picture on 
the left). By contrast, the FOG-1 zinc finger uses the DNA binding surface also as the protein interaction surface 
(contacts shown in green, picture on the right). Amino acid residues coordinating zinc ions are shown in dark 
blue. (B) Interaction of LIM domains (in light blue) of LMO4 with LIM interaction domains (in red) of lab1. 
Amino acid residues of LMO4 that participate in hydrophobic or electrostatic interactions are depicted in green. 
-sheets of both domains that pair up are shown in yellow (modified, [127]). 
 
 
In contrast to LIM domains, RING and PHD domains do not bind the two zinc ions 
sequentially, but interdigitated or ‘cross braced’ (Figure 1-13). RING domains are quite 
frequently found in E3 ubiquitin ligases, which catalyze the transfer of ubiquitin molecules 
from E2 transferases to the target protein. The RING finger can function as an interaction 
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domain with the E2 transferase, but can also possess intrinsic E3 ligase activity [127, 140], 
however, how this activity is mechanistically achieved by the RING structure is not solved 
yet. Recently, it could be shown that also the RING finger of human MSL2, which so far was 
only shown to function as a protein-protein interaction domain in Drosophila, is required for 
E3 ligase activity, at least in human cells [141]. In contrast to the related RING finger, PHD 
domains are often found in chromatin remodeling complexes and therefore a role in 
regulating chromatin structure is likely [142]. Indeed, PHD domains were shown to be able to 
bind to histones and to specifically recognize trimethylated lysine 4 of the N-terminal tail of 
histone H3 by forming a ‘cage’ of two or four aromatic side chains in which the trimethylated 
lysine side chain is trapped [143-145].   
 
1.7 Objectives 
In the field of eukaryotic gene regulation it is of major interest to understand the 
selective marking of an entire chromosome. A powerful model to study such a selection is the 
specific targeting of the X chromosome by the DCC in Drosophila melanogaster. Most of the 
knowledge about DCC targeting comes from in vivo studies, which frequently do not permit 
to dissect the underlying molecular mechanism. Especially the huge number of players and 
the complexity of their interactions in the in vivo situation cause problems. In contrast, the use 
of an in vitro system that makes use of purified components offer a way to dissect the 
molecular function of the single components involved. This study focuses on a single aspect 
of the multi-step targeting process: the interactions of MSL2 and MSL1 with nucleic acids. 
 In vivo studies suggest that the MSL2-MSL1 subcomplex serves as a binding module 
for the initial recognition of high affinity sites. However, a direct interaction of MSL2-MSL1 
with candidate binding sites has not been studied. Moreover, neither the precise nature and 
structure of binding sites, nor a DNA binding function within the subcomplex is known. To 
address these fundamental questions, a purified system comprised of recombinant proteins 
and synthetic nucleic acids was employed. The interaction of several protein derivatives 
lacking important domains with different kind of nucleic acid structures was quantitatively 
measured by using electrophoretic mobility shift assays. The relevance of those protein-
nucleic acid interactions for DCC targeting was in addition determined in vivo by using 
reporter gene assays and by localization studies of GFP-tagged proteins in cells.  
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2 Results 
2.1 Purification of recombinant MSL proteins 
In order to investigate the direct interaction of MSL proteins with candidate high 
affinity sites it was necessary to produce sufficient amounts of pure protein. As the 
heterologous expression system Sf21 cells (in combination with Baculovirus infection) were 
chosen and various MSL derivatives were purified using their C-terminal FLAG tags. In 
addition, the MSL2-MSL1 complex was coexpressed and copurified (with 1:1 ratio of both 
subunits) via the FLAG-tag of MSL2, whereas MSL1 was untagged. Besides expression in 
Sf21 cells, the CXC domain of MSL2 was also expressed in E.coli, but as a GST fusion 
protein. A schematic representation of all constructs and the Coomassie-stained protein 
preparations are shown in Figure 2-1. 
 
 
 
Figure 2-1: Overview of the various purified recombinant MSL proteins investigated in this study.  
(A) Schematic representation of MSL2 domain organization. FLAG and GST tags are shown in black. Numbers 
correspond to the amino acid positions in full-length MSL2. (B) Alignment of orthologue CXC domains from 
the Drosophila melanogaster MSL2 protein (DmCXC) and from the Homo sapiens protein KIAA1585 
(HsCXC). Black boxes show the conserved amino acids. Arrows indicate the introduced point mutations. (C) 
Coomassie-stained SDS-PAA gels of purified recombinant MSL proteins. 
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After having purified the MSL2-MSL1 complex from Sf21 cells the molecular mass 
and the stoichiometry of the complex was determined. For that purpose the purified complex 
(1:1 ratio of both subunits, Figure 2-1C) and the MSL2 protein were subjected to size 
exclusion chromatography (Figure 2-2). Both MSL2 and the MSL2-MSL1 complex do not 
elute at a defined molecular mass but rather elute over a wide range, indicating that both 
rather do not form a single, defined complex but exist as several complexes of different sizes. 
It seems that MSL2 and MSL1 are not forming a heterodimer (300 kDa) or heterotetramer 
(600 kDa) and that MSL2 by itself does not exist as a monomer (130 kDa). Interestingly, 
MSL2 and MSL1 seem to appear in equal amounts in every fraction, what suggests that a 
single MSL2 molecule interacts with a single MSL1 molecule. It is possible that the protein 
aggregates are only forming because MSL2 and MSL1 are taken out of the physiological 
context of the DCC, however it might well be that these aggregates are functionally 
important.  
 
 
 
Figure 2-2: Gel filtration to analyze the stoichiometry of MSL2 and the MSL2-MSL1 complex. 
Chromatogram of size separation of recombinant MSL2 protein (A) and MSL2-MSL1 complex (C). The black 
line is the measured absorption at 280 nm during the gel filtration run (Superose 6 column). Gray bars show the 
signal intensity (arbitrary units) of MSL2 and MSL1 protein in the individual fractions. The signal intensity was 
determined by quantification of MSL2 (B) or MSL2 and MSL1 (D) after TCA precipitation of the individual 
fractions, separation by SDS-PAGE and subsequent staining with Coomassie blue. Numbers correspond to the 
elution volume in ml. The elution volume of molecular weight standards (Thyroglobulin 670 kDa, ISWI 119 
kDa, BSA 66 kDa) is indicated. The exclusion volume of the Superose 6 column is marked with ‘Excl. vol.’. 
‘Inject’ represents 2% of the loaded material.  
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2.2 MSL2 is the DNA binding factor in the MSL2-MSL1 complex  
The MSL2-MSL1 complex is considered to serve as a binding platform that initially 
recognizes HAS on the X chromosome [79, 80]. But so far such a direct interaction of MSL2-
MSL1 with HAS has not been shown. Therefore the direct binding of MSL proteins to HAS 
was analyzed. As a model HAS, the recently by Gilfillan et al. isolated DCC binding 
fragment DBF12-L15 was used. This short 40 bp DNA element was found to be the minimal 
DNA sequence, which is sufficient to recruit the DCC in a reporter gene assay (Figure 1-9 
and [92]). It contains a proposed consensus sequence (GAAAGAGA), which is thought to be 
important for marking a DCC binding site in vivo [93, 94]. The purified recombinant MSL2, 
MSL1 and the MSL2-MSL1 complex (Figure 2-1C) were used and tested for their ability to 
bind the DBF12-L15 in electrophoretic mobility shift assays (EMSA). Indeed, MSL2 directly 
binds and forms a stable complex with the 40 bp DNA element in EMSAs (Figure 2-3).  
 
 
Figure 2-3: Binding of recombinant MSL proteins to a DNA HAS in vitro. Electrophoretic mobility shift 
assay. Increasing concentrations (from 5 nM to 250 nM) of MSL2 and MSL1 (A) or MSL2 and MSL2-MSL1 
complex (B) were incubated with radiolabeled double stranded 40 bp DBF12-L15 DNA and protein-DNA 
complexes were separated from unbound DNA in non-denaturing EMSA gels. (C) Binding curves obtained from 
quantification of (A) and (B) and fit to a standard bimolecular model (see ‘Material and Methods’). 
 
 
The affinity to DBF12-L15 can be determined from the binding curve and lies in the 
low nanomolar range (33 ± 18 nM). In contrast, MSL1 did not bind and did not form a stable 
protein-DNA complex with this short high affinity site (Figure 2-3A, C and Table 1). Since 
both MSL proteins are thought to act together in vivo, also the copurified MSL2-MSL1 
complex in EMSAs was tested (Figure 2-3B). The affinity of the MSL2-MSL1 complex to the 
high affinity site was similar to the affinity of MSL2 (Figure 2-3C and Table 1), meaning that 
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MSL1 does not contribute to the DNA binding ability of the MSL2-MSL1 complex. This 
strongly suggests that it is only the MSL2 protein, which is required for the recognition of 
HAS. 
 
2.3 The CXC domain of MSL2 is required but not sufficient for DNA 
binding 
Since a typical DNA-binding motif within the MSL2 or any other MSL protein has not 
been identified yet, different deletion constructs of MSL2 were tested for DNA binding to 
identify the responsible DNA binding domain. Within the MSL2 protein several domains 
have been described: The RING finger is the interaction domain for MSL1 [80] and the C-
terminal Pro/Bas patch was considered to be involved in RNA binding by an unknown, direct 
or indirect principle [99]. A function for the CXC domain, however, has not been assigned yet 
(Figure 1-10). Several MSL2 derivatives that lack one of the domains were constructed and 
purified (Figure 2-1A, C) and their affinity to the DBF12-L15 DNA element in EMSAs was 
measured (Figure 2-4 and Table 1).  
 
 
Figure 2-4: Binding of different recombinant MSL2 derivatives to a DNA HAS in vitro. (A) Electrophoretic 
mobility shift assays. Increasing concentrations of MSL2, MSL2-CXC, MSL2-RING and MSL2-Pro/Bas 
were incubated with radiolabeled double stranded 40 bp DBF12-L15DNA and protein-DNA complexes were 
separated from unbound DNA in non-denaturing EMSA gels. (B) Binding curves obtained from quantification 
of EMSA gels and fit to a standard bimolecular model. 
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The deletion of the MSL2 RING finger did not change the affinity of MSL2 to the DNA 
element. The affinity also did not change drastically, when the C-terminal Pro/Bas patch was 
removed. On the other hand, only the deletion of the CXC domain strongly reduced the 
affinity to the DNA, suggesting that it is the CXC domain, which mediates binding to HAS.  
The question arose whether the CXC domain by itself would still be able to bind DNA. 
Therefore the CXC domain was expressed alone, but fused to a GST or FLAG tag, and tested 
for its ability to bind DNA. Both the FLAG tagged and the GST tagged CXC domain could 
bind DNA by itself. However, the affinity was much lower (three orders of magnitude) 
compared to the full-length MSL2 protein (Figure 2-5). In other words the CXC domain is 
required but not sufficient for DNA binding. Additional regions within MSL2 are needed for 
full DNA binding. 
 
 
Figure 2-5: Binding of the isolated recombinant CXC domain to a DNA HAS in vitro. Electrophoretic 
mobility shift assay. Increasing concentrations (from 1 M to 8 M) of the GST tag alone and GST-CXC (A) or 
of CXC-FLAG (5 - 20 M) and GST-CXC (2 - 8 M) (B) were incubated with radiolabeled double stranded 40 
bp DBF12-L15 DNA and protein-DNA complexes were separated from unbound DNA in non-denaturing 
EMSA gels.  
 
2.4 Point mutations within the CXC domain affect DNA binding  
In order to confirm the novel role of the CXC domain as a motif, which is required for 
DNA binding, we created several mutations within the CXC domain (Figure 2-1B) and 
analyzed their effect on DNA binding. On the one hand two point mutations (cysteines to 
alanines), which were already described to affect development and viability of male 
transgenic flies [80], were simultaneously introduced within the CXC domain. On the other 
hand, a tyrosine to alanine substitution adjacent to one of the cysteines was created. The 
mutated MSL2 proteins were purified (Figure 2-1C) and tested in EMSAs (Figure 2-6 and 
Table 1). In fact, all mutations within the CXC domain reduced the affinity to DNA (33 nM 
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vs. 82 nM), but the effect was milder than the complete deletion of the CXC domain (189 
nM).   
 The CXC motif is conserved in the human MSL2 homologue [146]. To assess the 
DNA binding properties of the human CXC domain, a chimeric MSL2 protein was 
constructed (HsCXC, Figure 2-1B, C), where the CXC domain was replaced by a similar 
CXC motif of an orthologue Homo sapiens protein KIAA1585 [146]. Strikingly, the chimeric 
HsCXC protein exhibits the same affinity to DNA as the Drosophila melanogaster MSL2 
protein (Figure 2-6 and Table 1), pointing out the importance of the conserved amino acids 
(Figure 2-1B) of the CXC motif for DNA binding.  
 
 
Figure 2-6: Binding of different MSL2 point mutants and of the chimeric MSL2 protein to a DNA HAS 
site in vitro. Electrophoretic mobility shift assay. Increasing concentrations of MSL2 carrying point mutations in 
the CXC domain (A) or of the chimeric HsCXC protein (C) were incubated with radiolabeled double stranded 40 
bp DBF12-L15 DNA and protein-DNA complexes were separated from unbound DNA in non-denaturing 
EMSA gels. (B) and (D) Binding curves obtained from quantification of (A) and (C) and fit to a standard 
bimolecular model. For comparison MSL2 wildtype and MSL2CXC are displayed, too. 
 
2.5 Double stranded DNA is the preferred binding target for MSL2 
So far we demonstrated that MSL2 binds via its CXC domain to a double stranded (ds) 
DNA HAS. Since it is not known whether a HAS is in fact composed as a ds DNA element, 
we next asked if such a site would also be recognized when only one single DNA strand of 
the DBF12-L15 element was used or when the DBF12-L15 element was transcribed into 
RNA sequence, double and single stranded (ss). For this purpose a series of competition 
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assays was performed, where the relative affinities of MSL2 to other nucleic acids were 
measured (Figure 2-7). The competition curves showed that neither ssDNA nor ssRNA could 
compete with the MSL2-bound dsDNA. In contrast, dsRNA could compete the binding, 
nevertheless with a lower relative affinity compared to dsDNA (IC50 value 13.0 ± 6 nM vs. 36 
± 8 nM). In addition the competition curve for dsRNA has a slight sigmoid shape, indicating 
that there might be more than one binding site for RNA. 
 
 
Figure 2-7: Competition assays to assess selective binding of MSL2 to different nucleic acids. (A) 
Electrophoretic mobility shift assay. 50 nM of MSL2 was incubated with the radiolabeled 40 bp DNA element 
DBF12-L15 and then increasing concentrations (from 5 nM to 2080 nM) of unlabeled competitor nucleic acids 
were added. Shown is a representative example of competition with ds and ssDNA. (B) Competition curves 
obtained from EMSAs and fit to the model described in ‘Material and Methods’. 
 
 
The potential of MSL2 to directly bind RNA has not been appreciated so far and we 
were therefore interested to map the RNA binding domain within the MS2 protein. Different 
recombinant MSL2 truncations were used and their affinity to dsRNA was measured in 
EMSAs (Figure 2-8). Interestingly, the affinity of MSL2 to RNA was not affected by any of 
the truncations. Even the deletion of the CXC domain had no effect on RNA binding, which 
clearly demonstrates the function of the CXC domain as a specific dsDNA binding motif 
within the MSL2 protein. On the other hand, the region(s) responsible for RNA binding could 
not be located using this set of deletions. No further attempts were made since the focus of 
this project was on DNA binding domains. 
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Figure 2-8: Binding of different recombinant MSL2 derivatives to RNA. (A) Electrophoretic mobility shift 
assays. Increasing concentrations of MSL2 versions were incubated with radiolabeled dsRNA of DBF12-L15 
and protein-RNA complexes were separated from unbound RNA in non-denaturing EMSA gels. (B) Binding 
curves obtained from quantification of EMSAs and fit to a standard bimolecular model. 
 
2.6 DNA binding of MSL2 is sequence-independent  
According to a simple model, the recognition of the X chromosome by the DCC would 
involve binding of the DCC to a consensus sequence with higher affinity compared to non-
target sites. Here it was shown for the first time that MSL2 has the potential to serve as a 
DNA recognition module. In the next step, it should be tested whether MSL2 was able to 
distinguish HAS from random DNA. As a model HAS the DBF12-L15 DNA element was 
used. Mutations of the GA-rich consensus sequence to a stretch of thymines led to the 
DBF12-L18 sequence that was not anymore able to recruit the DCC in a reporter gene assay 
in cells (Figure 1-9 and [92]). We used those two dsDNA sequences, DBF12-L15 and L18, 
together with recombinant MSL2 protein in EMSAs and measured their binding affinities. 
Surprisingly, the affinity of MSL2 to a HAS was similar to a non-high affinity site (KD value 
33 ± 18 nM vs. 23 ± 8 nM, Figure 2-9A). Conceivably for a sequence-specific binding, not 
only MSL2 is needed, but in addition the MSL1 protein. We therefore included the copurified 
MSL2-MSL1 complex in our binding studies. Like the MSL2 protein, the MSL2-MSL1 
complex bound the high affinity site as well as the mutated site (data not shown), reinforcing 
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the fact that MSL2 is the single component required for the direct, however, sequence-
independent DNA binding.  
 
 
Figure 2-9: Binding of recombinant MSL2 to different DNA HAS in vitro. Electrophoretic mobility shift 
assays and binding curves obtained from quantification of EMSA gels and fit to a standard bimolecular model. 
Increasing concentrations of MSL2 were incubated with radiolabeled dsDNA of the model DBF12-L15 and the 
mutated high affinity site DBF12-L18 (A). (B) Same as (A) but with the DBF12-L15 trimer and a non-related 
multiple cloning site (mcs) or (C) with the roX1-DHS as DNA binding sites. Protein-DNA complexes were 
separated from unbound DNA in non-denaturing EMSA gels.  
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2.7 Affinity of MSL2 to DNA is increased with the length of DNA  
Previously it was shown that the single 40 bp DBF12-L15 DNA element by itself was 
rather weak in recruiting the DCC to both, a reporter gene in cells and an autosomal insertion 
site in larvae. However, as a trimer it produced one of the strongest recruitment sites detected 
so far [92]. Therefore it was tested whether such a trimerized DNA element would increase 
the affinity or selectivity of MSL2. As measured by EMSAs the affinity of MSL2 increased 
dramatically, when the DNA element was trimerized (from KD of 33 ± 18 nM to 0.59 ± 0.18 
nM). Surprisingly, a control sequence (the multiple cloning site of a cloning vector) of similar 
length produced a similar increase of affinity (Figure 2-9B and Table 1). MSL2 also bound a 
226 bp fragment derived from the roX1 gene, which is known to contain a HAS [83] with 
similar affinity (Figure 2-9C). In other words, the affinity of MSL2 increases with the length 
of the DNA, however, the specificity for a certain DNA sequence is not altered. 
 
Table 1: Comparison of binding affinities of different recombinant MSL2 derivatives to various nucleic 
acid binding sites. KD values were calculated from binding curves obtained from quantification of EMSA gels 
and fitting to a standard bimolecular model. Mean values are shown plus and minus the standard deviation from 
several replicates obtained with at least two independent protein preparations. For details see the ‘Materials and 
Methods’ section.  
 
       
MSL protein 
KD DBF12-
L15 
[nM] 
KD DBF12- 
L15 RNA 
[nM] 
KD DBF12-
L18 
[nM] 
KD DBF12-
L15 x 3 
[nM] 
KD 
 mcs 
[nM] 
KD  
roX1 DHS 
[nM] 
       
       
MSL2 33 ± 13 21 ± 4 23 ± 9 0.59 ± 0.18 0.61 ± 0.07 1.4 ± 0.87 
CXC 189 ± 18 29 ± 12     
RING 51 ± 5 23 ± 5     
Pro / Bas 61 ± 5 37 ± 10     
C544A / C546A 82 ± 4      
Y547A 81 ± 5      
HsCXC 33 ± 9      
MSL2 / MSL1 26 ± 15      
MSL1 no binding      
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2.8 Reporter gene activation in cells requires the CXC domain  
It was show that the CXC domain is indispensable for DNA binding of MSL2 in vitro. 
To confirm the relevance in vivo, the previously described reporter gene assay in Drosophila 
melanogaster SL2 cells was used ([92]). In this assay DCC binding sites are placed in front of 
a minimal promoter that drives transcription of a luciferase reporter gene. The plasmid is 
transfected into male Drosophila melanogaster SL2 cells together with a plasmid that allows 
expression of an MSL2-VP16 fusion protein. Upon binding of the MSL2 fusion protein to the 
binding element, the VP16 activation domain leads to the expression of the luciferase reporter 
gene (Figure 1-9 and Figure 2-10B). In this study, the different MSL2-VP16 constructs were 
tested for their ability to activate the reporter gene. Importantly, all MSL2 derivatives were 
expressed at a similar level (Figure 2-10A). Upon recruitment of MSL2-VP16 to the DBF12-
L15 binding site the luciferase reporter gene was activated roughly six-fold (Figure 2-10C in 
agreement with earlier results [92]). The MSL2 deletion RING was still able to activate the 
reporter gene, suggesting that this domain is not important for gene activation. Since the 
RING finger interacts with MSL1, the MSL1 protein seems to be not required for DNA 
binding in vitro, nor for transactivation in vivo. By contrast, MSL2 lacking the CXC domain 
or carrying point mutations in the same domain were not able to activate. Evidently, affecting 
the DNA binding function of the CXC domain also affects gene activation in vivo. Even 
lowering the affinity to DNA by only 3-fold (Table 1) completely prevents the activation of 
the reporter gene. The deletion of the Pro/Bas patch reduced reporter gene activity, however, 
still a robust two-fold activation was measured. Remarkably, the chimeric HsCXC protein, 
which binds DNA with wildtype affinity, did not mediate transactivation. Together these data 
suggest that the DNA binding function of MSL2 via its CXC domain is a prerequisite for 
gene activation, but that additional Drosophila factors may contribute.  
When the consensus DNA sequence in the DBF12-L15 DNA element was replaced by 
the mutated sequence in DBF12-L18 reporter gene activation with MSL2 as activator [92] as 
well as with all other MSL2 derivatives was abolished (Figure 2-10C), showing the 
importance of the GA-rich consensus sequence for MSL2 binding and / or gene activation in 
cells. In vitro, however, MSL2 bound both sequences with the same affinity. Again, all these 
findings suggest that DNA binding via the CXC domain is absolutely required, but other 
factors are needed to achieve specificity for a certain DNA sequence.  
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Figure 2-10: Reporter gene assay to measure transactivation potential of different MSL2 constructs in 
vivo. Drosophila SL2 cells were transiently cotransfected with different MSL2-VP16 constructs together with 
luciferase reporter gene constructs (pGL3-TK) carrying the model DBF12-L15 or the mutated site DBF12-L18 
(40 bp elements). A Renilla luciferase expression vector (pRL-TK) served as normalisation control. (B) 
Schematic representation of the cotransfected plasmids that constitute the reporter gene system (drawing is not to 
scale). (C) Transactivation potential of each MSL2 derivative is displayed as fold activation (for details see 
Materials and Methods). The black bars indicate a reporter gene bearing MSL2 binding sites (DBF12-L15), the 
white bars represent (lack of) activation in the presence of DBF12-L18. 
 
2.9 The CXC domain is necessary for targeting the DCC to the X 
chromosome 
Targeting of the DCC to the X chromosome is known to depend on the MSL2-MSL1 
heteromer. This study suggests that the direct interaction with DNA is brought about not by 
MSL1, but by the MSL2 protein, more precisely via its CXC domain. The reporter gene assay 
already suggested that this domain is also required for recruitment in vivo, at least to a single 
reporter gene. Whether also the targeting to the entire X chromosome involves the DNA 
binding function of MSL2 was addressed next. MSL2-CXC and MSL2-C544A/C547A 
derivatives, which show reduced affinity to DNA, as well as wildtype MSL2 were fused to 
GFP and stably expressed in Drosophila melanogaster SL2 cell lines. Western blot analysis 
showed that the stable cell lines express roughly the same amount of endogenous MSL2 and 
GFP-MSL2 (Figure 2-11A). Moreover, the level of expression was similar among all the 
transgenes. After several weeks of selection, the stable cell lines were analyzed for the 
localization of their MSL2-GFP protein (Figure 2-11B, C). The wildtype MSL2-GFP 
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colocalized perfectly with endogenous MSL1 to form a defined X-chromosomal territory in 
the nucleus. By contrast, when the DNA binding function of MSL2 was impaired also the X 
chromosomal targeting was disturbed: In around 75% of cells expressing the transgenes, the 
MSL2-CXC or MSL2-C544A/C547A-GFP fusion proteins did not form well restricted X 
chromosome territories, but were localized to many, dispersed foci in the nucleus (Figure 
2-11B). Interestingly, endogenous MSL1 perfectly colocalized with the mutated MSL2-GFP 
fusion proteins, showing that the interaction between MSL1 and the mutated MSL2 proteins 
is not disturbed (Figure 2-11C). More importantly, it clearly demonstrated that MSL1 cannot 
be maintained at its X chromosomal location without MSL2 and in turn followed MSL2 to 
ectopic sites. In summary, we conclude that for the proper targeting of the DCC in vivo, the 
functional DNA binding domain of MSL2 – the CXC domain – is required.  
 
 
Figure 2-11: In vivo localization of different MSL2 constructs. Stable Drosophila SL2 cell lines, which 
express different MSL2 versions fused to GFP, were analyzed by Western blot analysis (A) and by 
immunofluorescence staining (B) and (C). (A) Cells were harvested, lysed and roughly 0.05 x 106 cells were 
subjected to Western blot analysis. A rabbit anti-MSL2 antibody was used to detect the endogenous MSL2 and 
the different MSL2-GFP fusion proteins. (B) Examples showing single nuclei with proper targeting of MSL2 to 
the X chromosomal territory (left) or dispersed, non-physiological distribution of the GFP fusion proteins. (C) 
Representative fields of cells. Localization of MSL2-GFP constructs was visualized by using anti-GFP 
antibodies. Endogenous MSL1 was detected with anti-MSL1 antibodies. DNA was counterstained with DAPI. 
Cells that express the MSL2-GFP transgene were analyzed for proper X territory staining. The percentage of 
cells, which show mislocalized, dispersed GFP signals and the number of total cells counted are displayed.   
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2.10   Binding of MSL2 to RNA-DNA triplex structures 
As shown above, the binding specificity of the DCC in vivo is not brought about by 
different affinities of MSL2 to different DNA sequences in vitro. It might well be that a 
consensus sequence is indeed important, but that the representation as DNA sequence may be 
inappropriate. Examples are known, where DNA sequence has to be transcribed in order to 
serve as targeting elements [91, 147]. Consequently, a RNA-DNA triple helix could be an 
alternative target. Such triplexes are formed between homopyrimidine RNA and homopurine / 
homopyrimidine DNA sequences [148]. In fact, the proposed GA-rich consensus DNA 
sequence, as it is represented for example in the DBF12-L15 DNA element, contains a perfect 
homopurine / homopyrimidine recognition sequence and would be suited for forming a triple 
helix with a single stranded homopyrimidine RNA sequence, which might be represented in 
one of the roX RNAs. We therefore asked whether such a triplex would be a better-suited 
binding site compared to a DNA duplex.  
In a first step different RNA-DNA triplexes were formed and subsequently tested as 
binding sites for MSL2 in EMSA. We initially used well-described RNA and DNA sequences 
(triplex forming oligonucleotides, TFO, Figure 2-12B and [149]) to test whether triplex 
formation works under our conditions. In fact, by increasing the concentration of the single 
stranded RNA it was possible to convert a DNA duplex into a slower migrating RNA-DNA 
triple helix. A published 27 bp (21TFO-S) as well as our designed longer 40 bp DNA duplex 
(40TFO) was suited for triplex formation (Figure 2-12B, C and [149]). Unfortunately, the 40 
bp DBF12-L15 DNA did not form a triple helix with the corresponding 16 nt RNA (Figure 
2-12D).  
Nevertheless, EMSAs were performed, but not with DBF12-L15 but with the 40TFO 
DNA duplex and its corresponding triplex (Figure 2-12E, F). When the binding reaction was 
performed under conditions that ensure the formation of a stable triple helix (Figure 2-12C), 
MSL2 could not bind to the triple helix and also not to the 40TFO DNA duplex (data not 
shown). Consequently, triple helix formation was first carried out under the known triplex 
forming conditions, and then the binding reactions were carried out under the known 
conditions that allow MSL2 to bind DNA. Indeed, MSL2 formed a protein-DNA complex 
with the 40TFO DNA and also with its corresponding triplex, strikingly with roughly similar 
binding affinity (Figure 2-12E, binding curve not shown). However, the resolution of the 
native agarose gel does not allow a distinction between a duplex or triplex structure, making it 
impossible to clarify whether indeed a triplex structure was bound by MSL2, or whether the  
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Figure 2-12: Binding of recombinant MSL2 to duplex and triplex structures in vitro. (A) DNA triplex 
structure formed by an oligopyrimidine strand (yellow) and an oligopurine (red) / oligopyrimidine (blue) duplex. 
In the picture on the right, details of the base interactions are shown for a single DNA triplet motif (modified, 
[148]). (B) ssRNA and dsDNA sequences that were used for triplex formation. Triplex recognition motifs are 
underlined. (C)-(F) Electrophoretic mobility shift assays. Increasing concentrations (1, 2, 4 and 8 M) of 
different TFO RNAs were incubated with radiolabeled double stranded TFO (C) or DBF12-L15 (D) DNA 
duplexes. Duplex and triplex structures were then separated in non-denaturing agarose gels. Increasing 
concentrations (from 5 nM to 250 nM) of MSL2 were incubated with radiolabeled duplex and triplex structures 
(E) or with duplex and duplex:triplex ratio 1:1 (F) formed in (C). Protein-bound structures were separated from 
unbound duplex or triplex in native 1.2% agarose (E) or 12% PAA (F) gels. 
 
 
triplex has simply fallen apart. This could either happen because of unfavorable binding or 
EMSA conditions or by the action of MSL2. MSL2 could simply bind the DNA duplex 
within the triplex structure and lead to the dissociation of the triplex. To gain a better 
resolution for small molecules, native PAA gels were used and EMSAs with MSL2 and the 
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40TFO DNA duplex or a 1:1 mixture of triplex and duplex structure were performed (Figure 
2-12F). Again, a stable MSL2-DNA duplex complex was detected in native PAA gels, but it 
was again not possible to resolve duplex and triplex structures. Consequently, it remains 
unsolved whether a triplex is stable under the applied conditions or whether MSL2 simply 
promotes the dissociation of the RNA strand from the triplex by recognizing and binding to 
the duplex DNA within the triplex structure. Currently experiments are performed to test the 
formation of a triplex not under the known triplex forming conditions (as used in Figure 
2-12C, D) but under conditions, which are used for the subsequent MSL2 binding reaction. 
 
2.11   MSL2 is not sufficient for reporter gene activation in human 
cells 
Since the in vitro binding system works with purified and consequently known factors, 
it might well be that additional, yet unknown factors are required for specific targeting of the 
DCC. Therefore the requirements of additional factors, other than MSL2 and MSL1, for 
activation of a reporter gene were assessed, using a modification of the reporter gene system. 
The basic idea was to test whether MSL2 is able act autonomously in activation of a reporter 
gene in a human cell line or whether MSL2 needs additional factors that are exclusively 
present in Drosophila melanogaster and are not present in humans.  
The MSL-VP16 activation constructs and an inducible luciferase reporter construct, 
which contains one of the strongest DCC binding site – the roX1-DHS [83] – were transiently 
cotransfected into human HEK-293 cells and reporter gene activation, as an indirect measure 
for recruitment of MSL2 to the roX1-DHS was measured. The same experiment performed in 
Drosophila SL2 cells gives a huge activation of the reporter gene by MSL2 [92]. In HEK-
293, MSL2 expression was confirmed by Western blot (Figure 2-13A), however, no MSL2-
dependent activation of the reporter gene was observed (Figure 2-13B). The analysis was 
extended and dose-response experiments were performed (Figure 2-13C). By increasing the 
amount of transfected MSL2- or MSL1-VP16 activator constructs no activation, but rather a 
repression of reporter gene activity was measured. Yet, this effect was very mild and in the 
case of MSL1 the repression was also observed on a control luciferase reporter gene 
construct, which contained no binding site. Since MSL2 and MSL1 are thought to act together 
in vivo, we cotransfected MSL2 and MSL1, which again slightly reduced the reporter gene 
activity (fold activation from 1.3 to 0.8). In summary our results suggest that MSL2 is not 
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able to bind autonomously to HAS. Rather, it seems that one or more additional factors (other 
than MSL1) are required and that those factors are only present in Drosophila melanogaster. 
 
 
Figure 2-13: Reporter gene assay to measure the transactivation potential of MSL2 and MSL1 in a 
heterologous cell system. Human HEK-293 cells were transiently cotransfected with different MSL-VP16 
constructs together with reporter gene constructs carrying the roX1-DHS binding site or no binding site. (A) 
Western Blot of roughly 0.1 x 106 cells, which were harvested, lysed and proteins precipitated using TCA. A 
rabbit anti-MSL2 antibody was used to detect the different MSL2 constructs. (B) Transactivation potential of 
MSL2 and MSL2-CXC construct is displayed as fold activation. 112 ng of each MSL2 construct was 
transfected. (C) Increasing amounts (100, 300 and 600 ng) of MSL2 or MSL1 was transfected. ‘+’ indicates an 
unchanged amount (100 ng), while ‘-‘ means 0 ng of the individual transfected MSL constructs. 
 
2.12   Enrichment of a native DCC-containing fraction 
Since there is evidence for additional factors that might be involved in targeting the 
DCC (see chapter above) and which might have been missed so far in the in vitro binding 
assays, a native fraction containing the DCC was enriched by affinity chromatography and it 
was looked for associated factors. For that reason, Drosophila melanogaster SL2 cell lines, 
which stably express either FLAG-tagged MOF or FLAG-tagged MOF containing an 
additional Gal4 DNA binding domain (Gal4DBD, construct created by M. Prestel, P. Becker 
lab) from the endogenous MOF promoter were created. MOF was immunoprecipitated from 
nuclear extracts of those cell lines using FLAG-affinity chromatography and finally eluted 
after washing with different salt concentrations. The enriched native MOF-containing fraction 
was analyzed for its composition and associated factors by Western blot and mass 
spectrometry.  
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Figure 2-14: Enrichment of native DCC-containing fractions. Western blots with different antibodies on 
enriched Gal4DBD-MOF-FLAG (A) or MOF-FLAG (B) containing fractions after washing with 200 mM (1) 
and 400 mM (2) salt. (C) Silver stained SDS-PAGE gels of material used in (A) and (B) after 400 mM washing 
and Coomassie stained SDS-PAGE gels of (A). Cut gel slices that are subjected to mass spectrometry are 
numbered. (D) Binding of the enriched native Gal4DBD-MOF fraction (analyzed in (A) and (C)) to UAS sites in 
vitro. Electrophoretic mobility shift assays. Increasing concentrations of the Gal4DBD-MOF fraction were 
incubated with radiolabeled dsDNA of the consensus and the mutated UAS. Protein-DNA complexes were 
separated from unbound DNA in non-denaturing 0.7% agarose gels.  
 
 
Western blot analysis confirmed that indeed all known subunits of the DCC were 
associated with tagged MOF (Figure 2-14A), including the MLE helicase, showing indirectly 
that roX RNAs are also associated with the enriched fraction. Interestingly, the MOF 
transgene and endogenous MOF were purified in the same stoichiometry, indicating that an 
even number of MOF molecules exist within the complex (dimer, tetramer, etc.). The 
enriched fractions were subjected to mass spectrometry analysis (performed by the 
Zentrallabor für Proteinanalytik, Adolf-Butenandt-Institute, LMU) and identified proteins are 
listed below (Table 2 and Figure 2-14C). Besides the already known interactors, like MSL1, 
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MBD-R2 and components of the exosome complex, no other striking proteins were identified. 
A functional relevance of the exosome complex for dosage compensation is rather unlikely, 
despite the already described copurification with the DCC by other labs [63], since control 
purifications showed that the association of exosome components is mediated non-
specifically by the FLAG-agarose material (unpublished results, M. Prestel, P. Becker lab).  
 
 
Table 2: Identified proteins in the enriched native Gal4DBD-MOF fraction using mass spectrometry. 
Numbers correspond to the gel slices shown in Figure 2-14. Identified proteins are listed with a short description 
of their functions according to the shown references. ‘-‘ indicates that no protein was identified in the gel slice.  
 
    
No. Identified protein Description Reference 
    
    
1 karst (beta Heavy-spectrin) cytoskeleton of epithelial cells; 
rRNA processing 
[150] 
2 alpha spectrin cytoskeleton of epithelial cells [150] 
3 - - - 
4 MSL1 + MBD-R2 dosage compensation [63] 
5 MOF dosage compensation [63] 
6 Dis3 3'-5'-exoribonuclease activity; RNA binding [151] 
7 Rrp6 3'-5'-exoribonuclease activity; RNA binding [151] 
8 Hsp70 chaperone [152] 
9 beta tubulin + eukaryotic 
initiation factor 4B 
cytoskeleton mircotubules 
translation initiation 
[153] 
[154] 
10 eukaryotic initiation factor 4B translation initiation [154] 
11 actin 5C + eukaryotic initiation 
factor 4B 
actin cytoskeleton 
translation initiation 
[155] 
[154] 
12 Mtr3 3'-5'-exoribonuclease activity; RNA binding [151] 
13 - - - 
14 CG31938 3'-5'-exoribonuclease activity; RNA binding [151] 
    
 
2.13   DNA binding of an enriched native DCC fraction 
In order to test whether the native fraction enriched in DCC is suited for in vitro studies, 
initial DNA binding experiments were performed. Indeed proteins of the native fraction were 
specifically targeted to a known consensus upstream activator sequence (UAS) via the 
Gal4DBD of MOF (Figure 2-14D). A control UAS, which contains two mutations described 
to disrupt binding of the Gal4DBD [156], also disrupted the interaction between Gal4DBD-
MOF and DNA. These initial experiments indicate that in general sequence-specific binding 
can be detected using the in vitro system and that non-specific DNA binding activities are not 
detectable in the enriched fractions. Therefore this approach represents a starting point to 
study DNA binding in vitro, not only with recombinant but also with native fractions.       
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3 Discussion 
3.1 Multimerization of the MSL2-MSL1 complex 
The key subunits of the DCC – MSL2 and MSL1 – were expressed and purified as 
individual proteins and in form of a heteromeric complex. The analysis of the stoichiometry 
of the purified proteins revealed that MSL2 does not exist as a monomer but as a 
heterogeneous mixture of complexes with variable size – at least under the buffer conditions 
used in this study. The same is true for the MSL2-MSL1 subcomplex, which forms a complex 
larger than a heterotetramer of equal stoichiometry. Since no defined complex is formed, it is 
possible that during the gel filtration the MSL2 or MSL2-MSL1 complex is unstable and falls 
apart into different complexes of variable sizes. The MSL2-MSL1 subcomplex has not been 
analyzed so far and thus comparison with findings from other studies is not possible. 
However, a MSL2-MSL1-MSL3 complex could be purified from the male Drosophila 
melanogaster SL2 cell line and was analyzed by gel filtration [79]. A similar elution pattern 
over a wide molecular weight range was observed, despite the fact that a different source 
(recombinant versus native proteins) and different buffer conditions were used in their study 
[79]. The observed heterogeneity of complexes may be due to non-specific aggregation in the 
absence of a complete DCC. However, it is also possible that there might be a functional 
relevance for a large MSL2-MSL1 complex. For example, such an oligomerization may be 
responsible and even required for the very stable interaction of MSL2 in vivo as shown by 
FRAP analysis [100].  
In addition, formation of large multimeric protein complexes is not unusual for 
complexes that are involved in modifying chromatin architecture, as shown for the GAGA 
factor (GAF). It is thought that forming a multimer enables GAF to bring together different 
regulatory regions, which are otherwise separated by long distances, in order to create a single 
regulatory structure [157]. One interesting aspect about GAF are its self-association 
properties, mediated by two domains, the BTP/POZ and the polyglutamine-rich Q domain 
[158]. The Q domain by itself is capable of binding single stranded DNA, whereas the entire 
GAF protein is even capable of binding triple stranded DNA containing GA-repeats [159]. 
Given that there might be triple helix structures involved in dosage compensation, GAGA 
factor could be in principle a candidate binding protein (see below). The multimerization of 
GAF leads to complexes of 150 - 300 Å in diameter [160]. The formation of GAF multimers 
brings several DNA binding domains together and hence allows the interaction with several 
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DNA binding sites, which in turn enhances DNA binding. It was even shown by using 
electron microscopy that GAF is able to connect two separate DNA molecules in vitro [160]. 
A similar observation was also found in vivo, where GAGA enhancer sequences could 
activate transcription from a GAGA promoter by acting in trans, which means that both type 
of sequences were located on different plasmids [161]. This suggests that GAF acts in 
bridging enhancer and promoter sequence to bring those distantly located regulatory elements 
together. A similar mode of action could be proposed for the MSL2-MSL1 complex. First, in 
this study the MSL2-MSL1 complex was also shown to form multimers and second, it was 
recently shown that the MSL2-MSL1 complex sets up a male-specific organization of the X 
chromosome [96]. Measuring the 3D distances of HAS in male and female nuclei revealed a 
closer distance in males. Since reducing the levels of MSL2-MSL1 (but not of MSL3) by 
RNAi abolished the distance differences between male and female nuclei it is clear that this 
long-range interaction is dependent on the MSL2-MSL1 subcomplex. Oligomerization may 
therefore be required for MSL2-mediated clustering of HAS in vivo (Figure 3-1E and [96]).  
  
3.2 The DNA binding factor of the MSL2-MSL1 complex  
The current model of HAS implies that within the MSL2-MSL1 core unit, which is the 
minimal unit required for initial recognition of HAS, a DNA binding function must exist. This 
has never been shown – until now. By combining in vitro binding assays (EMSA) and 
recombinant MSL proteins, a DNA binding function within the MSL2-MSL1 complex was 
mapped. It is the MSL2 protein that is capable of DNA binding in vitro, whereas its 
interaction partner MSL1 is not. The fact that MSL1 is dispensable for DNA binding is rather 
surprising, since Scott and colleagues proposed that within MSL1 a short N-terminal region 
might be required for binding to DNA [98]. This was based on the observation in transgenic 
flies that a MSL1 truncation, which lacked the first 26 amino acids, was not associated with 
the polytene X chromosome anymore. However, the mechanism was not addressed. The 
deletion could have affected the targeting, e.g. by impairing DNA binding or simply by 
disrupting the nuclear localization. In an earlier study the same group showed that MSL2 
binding to the polytene X chromosome was reduced, but not abolished when MSL1 lacked 
the first 76 amino acids [97]. MSL2 therefore does not need the N-terminal region of MSL1 
for X chromosome binding. Although its ability may be reduced in the absence of MSL1, 
MSL2 clearly has the ability to bind the X chromosome by itself. Those in vivo findings 
support our in vitro data, which suggests MSL2 as the factor that binds to DNA.  
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Despite the fact that MSL1 itself is not capable of DNA binding it could indirectly 
influence DNA binding of its partner MSL2. Such heterodimer formations are quite common 
for many DNA binding proteins, for example the very large family of steroid hormone 
receptors. Those ligand-activated transcription factors share a well-conserved DNA-binding 
domain, which upon dimerization allows the binding to hexameric hormone response 
elements, either oriented as direct or inverted repeats [125]. Some members of the nuclear 
hormone receptors, for example the retinoic X receptor RXR, are able to bind as a 
homodimer, but forming a heterodimer with different other hormone receptor monomers, 
such as the vitamin D3 or thyroid hormone receptor, is known to alter the affinity and 
selectivity for the DNA binding site [126]. Judged from the results presented in this study 
such a mode of action is not the case for MSL2 and MSL1, since the MSL2-MSL1 complex 
has the same affinity for DNA as the MSL2 protein alone, showing that MSL1 does not 
increase the affinity of the heteromer. It can be concluded that MSL1 is not needed for DNA 
binding. This finding is supported by results from the in vivo reporter gene assay: When the 
domain that is required for interaction with MSL1 – the MSL2 RING finger – was deleted, 
the reporter gene activation could still be stimulated. This demonstrates that MSL2 is able to 
act without MSL1 in cells. The summary of our in vitro and in vivo binding data leads to the 
hypothesis that it is mainly MSL2, which endows the DCC with DNA binding capacity.  
 
3.3 CXC domains as DNA binding modules 
3.3.1 DNA binding by the CXC domain of MSL2 
In this study, the DNA binding domain within MSL2 was mapped to the CXC domain 
and it was found to be required but not sufficient for DNA binding. In addition it was shown 
that the impaired DNA binding function also correlated with impaired targeting of the DCC to 
the X chromosome in vivo. Surprisingly, previous studies did not highlight the CXC domain 
as needed for X chromosome targeting. A series of MSL2 truncations had been analyzed in 
transgenic flies for their ability to bind to the polytene X chromosome [99]. Deleting a large 
region that included the CXC domain and the Pro/Bas patch led to a displacement from the 
usual binding sites to the pericentromeric heterochromatin. A construct that included again 
the CXC domain did not change this mislocalization, which led the authors to speculate that 
the CXC domain was not needed for targeting. However, this conclusion cannot be drawn, 
since all MSL2 truncations tested in their assay perturbed MSL2 function. Only when all 
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domains were present, which is in fact almost the full-length protein, MSL2 could localize 
normally to the thousands of sites on the X chromosome [99].  
In order to further characterize the role of the CXC domain for DNA binding, two point 
mutations of conserved cysteines within the CXC domain were tested in addition. As for the 
deletion of the complete CXC domain also for the point mutations it was confirmed that 
impaired DNA binding is correlated with impaired in vivo targeting in cell culture. The in vivo 
relevance of the point mutations is not only based on our results in cells, but is further 
supported by early work from the Kuroda lab with transgenic flies [80]. The very same point 
mutations did not cause lethality for male flies, however, fly development was delayed and 
their viability reduced [80]. The in vitro studies presented here would therefore offer an 
explanation for this in vivo defect, namely that the mutation of the conserved cysteines 
disturbs, but does not abolish the DNA binding function of the CXC domain, which 
consequently leads to reduced affinity of MSL2 to DNA. Since the affinity is only reduced 
and DNA binding is not completely destroyed the effects on male viability are also not that 
extreme.  
It is possible that in MSL2 the CXC domain cooperates with other structures, such as the 
Pro/Bas patch. The deletion of this patch led to a slightly lower affinity of MSL2 for nucleic 
acids and to a modest reduction of MSL2 targeting to a HAS in cells. Further evaluation of 
these hypotheses will require knowledge of the MSL domain structures at atomic resolution. 
 
3.3.2 CXC domains and their function in DNA binding  
The CXC domain is not only found in the MSL2 protein, but also other proteins, from 
plants to humans, contain CXC domains, with the exceptions of yeast and other fungi [146]. 
According to Marin these CXC domains can be placed into different groups, which vary in 
their N-terminal sequence: The Enhancer of Zeste E(Z), the TSO-1 and the MSL2 CXC 
domains [146]. Common to all groups is the presence of one to three CXC motifs at the N-
terminal part and the general C-X4-CXC-X6-C-X4-5-C-X2-C formula at the C-terminal end of 
the domain. Often two CXC domains occur separated by a variable linker length within the 
same protein. [146]. Not only in MSL2, but also in other Drosophila proteins, as well as in 
plant proteins several mutations of the conserved cysteines have been described [80]. For 
example mutations in the genes of Drosophila enhancer of zeste [162] and of Arabidopsis 
thaliana TSO-1 [163, 164] are known to cause developmental defects in the animals and in 
the plant. But it remained unclear how those mutations affected the function of the protein. 
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Recently, the tesmin/TSO1-like protein from Arabidopsis thaliana, which is composed of two 
CXC domains separated by a conserved linker region, was analyzed in vitro for its ability to 
bind different metal ions [165]. Zinc was the preferred metal ion that was bound, probably at 
least four zinc ions per two CXC domains [165]. Therefore replacing cysteines could impair 
chelating of zinc ions and subsequently could affect protein function. Two recent studies on 
novel Drosophila testis-specific protein complexes (tMAC) identified proteins of the 
tesmin/TSO1-family (dMip120 and Tombola), which share one or two CXC domains, 
respectively [166, 167]. Drosophila Mip120 was already found in the dREAM complex, 
which functions in DNA replication [168] and repression of a subset of genes with 
developmental- or sex-specific expression patterns [169, 170]. Similar to polycomb 
complexes, dREAM associates with transcriptionally silent chromatin, however, the binding 
sites of polycomb and dREAM complexes do not overlap [169]. Direct binding to DNA is 
likely achieved by the action of Mip120. In the testis-specific tMAC complex, Mip120 was 
not found, but a different family member, Tombola, which in contrast to Mip120 possesses 
only one CXC domain [166, 167]. Interestingly, two proteins of the tMAC complex (Topi and 
Achi/Vis) are thought to have inherent sequence-specific DNA-binding activity. This would 
mean that several DNA binding functions are contained together in the same complex, 
offering a way to increase the repertoire of potential DNA binding sites [167]. It is also 
speculated that two of the proteins (Topi and Achi/Vis) could bind with low affinity to the 
target promoter. The presence of the CXC domain containing protein Tombola could allow 
then the interaction with the two others, which in turn would lead to cooperative DNA 
binding [167]. It should be mentioned that cooperativity would not necessarily require direct 
binding of Tombola to DNA; a DNA-independent interaction with the two other, already 
DNA bound, proteins could be sufficient. Whether the CXC domain of Tombola is indeed 
functioning as a DNA binding structure has to be shown. 
 
3.3.3 The CXC domain – a conserved DNA binding module 
So far DNA binding was only demonstrated for one related member of the tesmin/TSO1-
family: The CPP1 protein of the soybean is involved in the regulation of the expression of 
leghemoglobins, which are needed in the symbiotic root nodule to transport oxygen to the 
respiring bacteria [171]. It could be shown that the two clustered CXC domains of CPP1, 
which are separated by approximately 60 amino acids, are sufficient to bind DNA in vitro. In 
addition, the two CXC domains were able to specifically bind to a promoter fragment of a 
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leghemoglobin gene, showing that the CXC domains alone are sufficient to provide binding 
specificity [171]. Since both CXC domains have the same general CXC formula (see above) 
like MSL2 and others, it is clear that other N-, C-terminal and linker regions must contribute 
to the recognition in order to ensure binding to the correct target sequence. The affinity of the 
CPP1 CXC domains to DNA, however, was not determined precluding a comparison with 
results obtained in this study. When just the CXC domain of MSL2 by itself was used, DNA 
binding could be detected, too. Nevertheless, the affinity was much weaker compared to the 
full-length MSL2 protein, indicating that – in contrast to CPP1 – additional regions of MSL2 
were required for high affinity binding.  
Because of the increased insight into the roles of CXC domain containing proteins it is 
tempting to suggest that all members of this protein family use their CXC domain to directly 
contact DNA [166]. However, such a function has to be proven experimentally for every 
single protein. But such a common role of those domains is consistent with our finding that a 
related CXC domain from a Homo sapiens protein can functionally replace the original 
Drosophila melanogaster CXC domain of MSL2 in DNA binding in vitro. About the human 
KIAA1585 protein not much information exists. It was discovered in a cDNA screen of 
unidentified human genes [172]. Homology database search classified the protein as being 
similar to Drosophila melanogaster MSL2 [146]. KIAA1585 and MSL2 were the two only 
proteins found in the databases that share the unique combination of a RING finger and a 
CXC domain, suggesting that they may form a functional module [146]. The data presented 
here do not support this speculation, since deleting the RING finger does neither affect DNA 
binding nor reporter gene activation in cells. Obviously for the complete function of MSL2, 
both domains are needed and maybe might even form intramolecular interactions. The CXC 
domains of MSL2 and its human orthologue share one N-terminal CXC motif, which is linked 
to the C-terminal C-X4-CXC-X6-C-X4-5-C-X2-C motif by a spacer of the same length (11 
amino acids). Several amino acids between the conserved cysteines (depicted as X in the 
formula) are also identical [146]. The similarity of the conserved cysteines and their spacing 
are indeed sufficient to enable DNA binding. On the other hand, the chimeric MSL2 protein 
could not activate the reporter gene in vivo, showing that for MSL2’s transactivation ability, 
in contrast to its DNA binding ability, also the non-conserved amino acids are needed.   
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3.4 MSL2 – an additional RNA binding protein within the DCC   
The in vivo crosslinking analyses had pointed to sequence motifs that are enriched in 
HAS [93, 94], but they could not distinguish whether these sequences attract the DCC as 
double stranded or single stranded DNA or as RNA. The relative affinities of MSL2 for the 
DBF12-L15 sequence presented in the form of ss and dsDNA or RNA was determined in a 
series of competition assays. Single stranded nucleic acids could not be bound by MSL2, 
showing that the structure of a double helix is an essential feature that is used by the protein 
for recognition of the target site. However, we also observed binding of MSL2 to dsRNA 
(with similar affinity), which is quite surprising, since so far only the DCC components 
MSL3 and MOF were shown to be able to bind RNA, whereas MSL2-chromosome 
interactions in vivo are relatively RNAse-insensitive [173, 174]. The RNA binding is not 
brought about by the CXC domain and also the RING finger and the Pro/Bas patch are 
dispensable for RNA binding, showing that the RNA binding function within MSL2 cannot 
be located. It was speculated by Scott and colleagues that the Pro/Bas patch, which is 
positively charged because of a cluster of basic amino acids, might be responsible for roX 
RNA binding. Such a simple positively charged stretch is found frequently within RNA 
binding domains and is a way for proteins to form contacts with RNA. The deletion of the 
Pro/Bas patch modestly reduced MSL2-mediated activation of the reporter gene, which points 
to a role for this patch in vivo. On the other hand, RNA binding in vitro was almost not 
affected, but it might well be that after deleting the Pro/Bas region, the RNA is bound by 
another, secondary binding domain (the CXC domain or the RING finger). The observed 
slight sigmoid shape of the competition curve would support this idea of the existence of 
more than one RNA binding site within MSL2. The presence of an additional novel RNA 
binding protein within the DCC would offer new exciting possibilities of regulating dosage 
compensation.    
 
3.5 Recognition of high affinity sites 
This study documents the first quantitative measurements of the binding of MSL 
proteins to a potential DNA HAS. The affinity constant KD of MSL2 to the short 40 bp 
DBF12-L15 DNA element is around 33 nM. Such low nanomolar affinities are not unusual 
and in fact are typical for other DNA binding proteins, such as hormone receptors, which bind 
specifically to their consensus hormone response elements. For example recombinant 
glucocorticoid receptor (GR) was tested in gel shift assays for its ability to bind to different 
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hormone response elements. GR bound in vitro a 33 bp long DNA sequence, which contained 
a consensus hormone response element, with a KD of around 21 nM [175]. In contrast to this 
high affinity binding, the same receptor bound a related response element of the androgen 
receptor with only low affinity (165 nM) [175]. The difference between 21 versus 168 nM 
does not seem to be large, but an eight times reduced affinity can have a strong impact on the 
in vivo function: The reduced affinity of GR to the target sequence led to a drastic reduction 
of GR-induced transcriptional activation (from 7 to 1.6 fold activation) in cell culture [175]. 
Moreover, interfering with the DNA binding function does not only show effects in cell 
culture systems, but can also have serious consequences for the health of an entire organism. 
The androgen insensitivity syndrome in humans is characterized by the inability to respond to 
the hormone. One cause for this syndrome can be mutations within the androgen receptor and 
its DNA binding domain. This example clearly illustrates that also a six times reduced affinity 
(from 33 to 189 nM) of MSL2-CXC in comparison to the wild type protein can suffice to 
affect the protein function also in vivo. Indeed a similar reduction of MSL2-induced reporter 
gene activation (from 6 to 1 fold) and a mislocalization of MSL2 in cell culture were 
observed.  
Currently it is thought that the hierarchy of DCC binding sites observed in vivo is based 
on their different affinities to a DCC subcomplex. However, recombinant MSL2 bound all 
DNA sequences with similar affinity. Since clustering of several sequence motifs was shown 
in vivo to create an even stronger HAS [92], a trimerized DNA element and in addition the 
well-characterized HAS within the roX1 gene [83] was also tested. The affinity of MSL2 to 
those HAS was indeed increased (KD around 1 nM), but again, a control DNA with similar 
length was bound equally well. In summary, MSL2 is capable of DNA binding, however, 
binding is sequence-independent and it seems that affinity depends on the length of the DNA, 
simply because more binding sites are available. The simple model by which the MSL2-
MSL1 subcomplex distinguishes target sequences just because of different affinities cannot be 
confirmed by the in vitro findings presented in this study. 
 
3.6 Alternative binding mechanisms  
So which other principles may contribute to binding selectivity? It is obvious that our 
purified in vitro system so far includes a few components. It may well be that additional 
factors are required for achieving sequence-specific binding. Previously, the role of roX 
RNAs was proposed to alter the binding specificity of the MSL2-MSL1 complex by an 
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unknown principle, but needing the Pro/Bas patch [99]. However, it has to be noted that in 
this in vivo study not only the deletion of the Pro/Bas patch, but also other MSL2 deletions 
disturbed the targeting of MSL2 to the polytene X chromosome. Only when all domains of 
MSL2 were present roX RNA could efficiently be incorporated (by the known RNA binding 
proteins of the DCC) and consequently the regular targeting was achieved [99]. 
Consequently, the role of the Pro/Bas patch as a RNA binding domain is not convincing yet 
and needs further examination. The data presented in this study does not exclude a role of the 
Pro/Bas patch in HAS binding via roX RNA incorporation: RNA binding of MSL2 in vitro is 
slightly altered when the Pro/Basic patch is deleted, however, the binding affinity is decreased 
by less than 1.5-fold. The same MSL2-Pro/Basic protein shows a reduced activation of the 
reporter gene, yet it is still a robust two-fold activation. In summary, the Pro/Bas patch and 
roX RNA might play a role for binding to HAS in vivo, but how this could be achieved is still 
not understood. 
 
3.6.1 The nature of HAS: Involvement of triple helix structures?  
So far it is not clear in which conformation the sequence that characterize HAS have to 
be presented. A non-B form DNA, a triple helix structure, or the context of chromatin might 
be required. The nucleosomal organization of the candidate sequence was not explored since 
HAS tend to reside in nucleosome-free regions [93, 94]. Instead, the involvement of triple 
helix structures was addressed: roX RNA might play a role in sequence-specific recognition, 
but not by interaction with the MSL2-MSL1 complex but rather by specific interaction with 
the DNA high affinity site itself. Such a RNA-DNA triplex could then be a more specific 
target for MSL2 (Figure 3-1B). The main question is, whether a HAS would be suited for 
triplex formation. The DNA major groove possesses several acceptor and donor groups that 
would allow hydrogen bonding with a third strand. This also means that not every sequence is 
suited for forming a triplex [148]. For example the homopurine strand of the duplex can 
contact a third strand (homopyrimidine) by forming T-A*T and C-G*C+ base triplets; 
however, a requirement is that the imino group of cytosine is protonated. But since its pKa is 
well below 7, the protonation only works under acidic pH conditions [176], which 
dramatically reduces the applicability of triplex formation in vivo. A screening under neutral 
pH conditions, revealed that a homopurine-homopyrimidine DNA duplex could be bound by 
RNA strands containing only pyrimidines, yet, the affinities were much weaker at neutral pH 
by comparison to pH 6.0 (57 versus 400 nM) [149]. It is striking that HAS are characterized 
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by GA repeats (homopurines), which would in theory be suited for formation of a triple 
helical structure with a third homopyrimidine RNA molecule. Our initial experiments showed 
that triplex formation with a perfect recognition motif is possible, but the short homopurine 
stretch in the 40 bp long DBF12-L15 HAS was not sufficient to bind the homopyrimidine 
RNA strand. Triplex formation was discussed to be involved in several biological systems. 
For example triplex formation at AG-rich satellite repeats of Drosophila could be possible in 
vivo, since the physiological copper concentration allows triplex formation even at neutral pH 
[177]. In the telomerase enzyme, which copies a short fragment of its integral telomerase 
RNA onto the ends of eukaryotic chromosomes, a triple helix formed only by RNA molecules 
was found to be essential for its function [178]. Also the GAGA factor (GAF) was shown to 
bind triple stranded DNA in vitro [159], which is discussed in the section below. In the 
context of dosage compensation it has been already tested, whether roX RNA could form an 
RNA-DNA duplex or triplex with roX1 or roX2 DHS in vivo. The deletion of roX RNA 
fragments that were complementary to the DNA binding site did not affect DCC binding to 
the roX binding sites on the polytene X chromosome, ruling out an involvement of at least 
those triplex structures formed between roX RNA and the DHS, in target site recognition 
[84].  
 
3.6.2 Factor X required for sequence-specific binding? 
Alternatively, an unknown protein factor X could be involved in the sequence-specific 
DNA binding (Figure 3-1C). Two scenarios are plausible: Factor X could have an intrinsic 
binding specificity for the consensus sequence and after its binding to DNA may recruit the 
MSL2-MSL1 complex whose sequence-independent DNA binding may then stabilize the 
interaction at this site. Alternatively, factor X could interact with MSL2-MSL1 to alter the 
complex conformation, which then could cause cooperative, that is sequence-specific binding 
to the consensus sequence. It should be highlighted that the proposed mechanisms require the 
DNA binding ability of MSL2, in order to provide a first unspecific contact with DNA or to 
stabilize the interaction with DNA. The question was addressed whether additional factors 
besides MSL2-MSL1 are needed for recognizing a HAS in vivo. In human cells that should 
not contain a HAS co-factor, MSL2 and MSL1 affected transcription of a reporter gene only 
very weakly. Moreover, this mild effect was independent of the binding site: Independent of 
whether the reporter gene construct carried the roX1 DHS high affinity site or not, this mild 
decrease of activation was observed. By contrast, in Drosophila SL2 cells the roX1 DHS 
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caused a strong, 20-fold MSL2-dependent activation [92]. These results favor the idea that 
MSL2-MSL1 are not sufficient to recognize HAS and that an additional factor exists, which is 
specific to Drosophila. It has to be noted that MSL2 and MSL1 could in fact work in another 
system than Drosophila. In a yeast two-hybrid assay, MSL2 and MSL1 were attached to a 
Gal4DBD and both fusion proteins led to activation of transcription upon binding to a UAS 
binding site [79]. One can conclude from those finding that an activation potential, either 
intrinsic or brought about by interaction with other transcriptional activators, is functional in 
yeast, however, it is the DNA binding function that is affected in other systems. Of course this 
could simply be because of wrong folding or missing posttranslational modifications of the 
protein, but also because a factor X, which brings about specificity, is not present in the 
artificial in vitro and also not in other in vivo systems.  
The occurrence and clustering of GA repeats in HAS led to speculations about an 
involvement of the GAGA factor (GAF) in dosage compensation. GAF is known to act in 
cooperation with activating trxG (trithorax group) as well as with silencing PcG (polycomb 
group) complexes to activate or repress expression of homeotic genes, which control the 
proper realization of the body plan during animal development [157]. Homeotic genes as well 
as other developmental genes contain GAGA motifs to which the GAF is recruited [179, 
180]. Its DNA binding domain, which is composed of a classical Cys2His2 zinc finger and 
three short basic regions [181, 182], was by itself able to specifically bind to GAG 
trinucleotide sequence in EMSAs [183]. Moreover, GAF’s Q domain by itself is capable of 
binding single stranded DNA, whereas the entire GAF protein is even capable of binding 
triple stranded DNA containing GA-repeats [159]. Given that there might be triple helix 
structures involved in dosage compensation (see above), GAGA factor could be in principle a 
candidate binding protein. Since GA repeats were found in the proposed DCC consensus 
sequence (MRE), it was speculated that GAF could be factor X that binds to the target 
sequence and subsequently could recruit MSL2-MSL1. To investigate this idea GAF protein 
levels were reduced in SL2 cells by using RNAi, however, the activation of the reporter gene 
was not affected (C. König, P. Becker lab, unpublished results). Interfering with GAGA 
function in flies showed on the one hand increased male lethality but on the other hand MSL2 
was still normally localized to its binding sites on the polytene X chromosome [184], 
excluding a role of GAF in dosage compensation.  
GAGA motifs, although they have to be presented as longer stretches, can also be 
bound by another developmental regulator, the Pipsqueak protein, using a conserved helix-
turn-helix motif [185]. Pipsqueak and GAF colocalize to hundreds of sites on the polytene 
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chromosomes, and protein-protein contacts are meditated via their BTB/POZ domains, 
suggesting that both proteins have similar functions [186]. Hence it is possible that disrupting 
GAF function by RNAi or by mutations in the coding gene as done in the experiments 
mentioned above will be without effect because Pipsqueak could carry out GAF’s function.  
 
3.6.3 High affinity sites as allosteric effectors?    
In this study sequence-specific binding of MSL2 was not shown, however, affinity 
differences may not be necessary for the targeting to HAS (Figure 3-1A, D). The following 
scenarios may be considered. The NF-B transcription factors bind to a relatively loose 
consensus sequence and it is not clear how these sequences define specific binding sites. It 
was found that the binding site does rather not determine the effectivity of binding, but it 
determines which coactivators get recruited to the NF-B transcription factors [187]. This 
indicates that the DNA sequence is not just a docking site but can influence the conformation 
of the DNA-binding protein and subsequently change its function. A similar mode of action 
was proposed for the glucocorticoid receptor (GR). It was often found that despite the high 
affinity of the GR to a binding site the transcriptional output was low or that even a very weak 
affinity (> 1000 nM) led to extremely high transcriptional activation [188]. This suggests that 
selective activation is not only determined by the affinity to a certain DNA sequence. The 
DNA sequence was shown to trigger a conformational change within the DNA binding 
domain of the GR and as a consequence affected the regulatory activity of the protein [188]. 
Moreover, selectivity for target sequences do not need to be based on binding affinity, but 
rather on conformational changes subsequent to binding, as shown for DNA topoisomerase II. 
In the context of the DCC the following scenario may be envisioned: MSL2 would scan DNA 
using the sequence-independent binding ability of its CXC domain. Only when a particular 
sequence (e.g. HAS) acts as an allosteric effector it would trigger a conformational change 
within MSL2 which subsequently would allow effective recruitment of MSL1 or assembly of 
the entire DCC (Figure 3-1D).  
 
3.7 Outlook 
In this study, the direct interaction of recombinant DCC proteins with candidate binding 
sites was analyzed. Indeed, employing a biochemical approach allowed assigning a DNA 
binding function within the DCC, however, with no preference for certain DNA sequences in 
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vitro. The simple mechanism by which the DCC recognizes target sites based on their affinity 
cannot be confirmed by this study suggesting that other targeting principles must be involved 
(Figure 3-1). Within this work, indications for an unknown specificity factor, which is only 
present in Drosophila, emerged. Its identification and biochemical characterization would be 
crucial for understanding X chromosome targeting. Alternatively, sequence-specificity does 
not necessarily have to be based on affinity differences, but rather on triggering a 
conformational change by the target sequence. However, obtaining proof for such a 
mechanism is only possible by extending the biochemical analysis and ideally combining it 
with structural data of the MSL2-MSL1 complex. 
 
 
Figure 3-1: Alternative targeting principles. In all cases, the CXC domain of MSL2 is required for 
establishing protein-DNA contacts, whereas MSL1 is dispensable for DNA recognition, but might be needed for 
association with chromatin (not illustrated here). (A) Recruitment is based on different affinities of MSL2 to 
target and non-target sequences. However, biochemical data presented in this study does not support this model. 
(B) The recognition of target sites by MSL2 requires triple helix formation, e.g. between dsDNA of HAS and a 
single stranded region of roX RNA. (C) Sequence-specific DNA binding is mediated by binding of an unknown 
factor X, which is specific for Drosophila. Nevertheless, binding of MSL2 via its CXC domain is needed for 
stabilization. (D) The target site DNA (e.g. HAS) triggers a conformational change in MSL2, allowing efficient 
recruitment of MSL1 or other DCC subunits. (E) Multimerization of MSL2-MSL1 is needed to bring HAS 
together to form a male-specific nuclear compartment. The models proposed here are not mutually exclusive and 
can be combined. For example factor X (C) might be required to bind the triplex structures (B) and 
multimerization (E) does not necessarily require a conformational change of MSL2 (D) but could occur for all 
other MSL2 states as well (A-C) (pictures were created using the motifolio toolkit). 
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4 Materials and Methods 
4.1 Materials 
4.1.1 General chemicals  
All common chemicals were ordered from Merck (Darmstadt), Roth (Karlsruhe) or 
Sigma (Taufkirchen), exceptions and special chemicals are listed below. 
Acrylamide (Rotiphorese Gel 30)   Roth, Karlsruhe 
Agarose (LE GP)     Biozym, Hessisch Oldenburg  
[-32P]- ATP      Perkin Elmer, Waltham, MA, USA 
BSA (Bovine serum albumin), 98% pure  Sigma, Taufkirchen 
BSA, purified      NEB, Frankfurt/Main 
Coomassie G250     Serva, Heidelberg 
[-32P]-dCTP      GE Healthcare, Munich / 
       Hartmann Analytic, Braunschweig 
dNTP (single)      Roche, Mannheim 
FLAG peptide      Sigma, Taufkichen 
Formaldehyde      Polysciences, Inc., Warrington, PA 
Glutathione      Sigma, Taufkirchen 
IPTG       Roth, Karlsruhe 
NP-40 (Igepal CA-630)    Sigma, Taufkirchen 
PMSF (Phenylmethanesulfonyl fluoride)  Sigma, Taufkirchen  
Protease inhibitors: Aprotinin, Leupeptin,   Sigma, Taufkirchen 
Pepstatin 
Spermidine trihydrochloride    Sigma, Taufkirchen 
Triton X-100      Sigma, Taufkirchen 
Tween 20      Sigma, Taufkirchen 
 
4.1.2 Chemicals for tissue culture 
Blasticidin      A.G. Scientific, San Diego, CA, USA  
Gentamycin      PAA, Cölbe 
Penicillin / Streptomycin    Sigma, Taufkirchen 
Trypan Blue      Sigma, Taufkirchen 
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Effectene Transfection Reagent   Qiagen, Hilden 
FuGENE HD Transfection Reagent   Roche, Mannheim 
FBS (fetal bovine serum)    Sigma, Taufkirchen 
DMEM High Glucose 4.5 g/L   PAA, Cölbe 
(+ L-Glutamine, + Sodium Pyruvate) 
Schneider’s Drosophila medium   Invitrogen, Karlsruhe 
(+ L-Glutamine) 
Sf-900 II SFM Medium    Invitrogen, Karlsruhe 
 
4.1.3 Antibodies 
Primary antibodies 
MSL2 polyclonal rabbit serum (SABC), used 1:1000 in WB  
MSL1 polyclonal rabbit serum, used 1:1000 in WB and IF, kind gift from E. Schulze 
MSL3 affinity purified monoclonal mouse antibody (clone 1C9-5), used 1:50 in WB 
MOF  polyclonal rabbit serum (SA4897), used 1:1000 in WB 
MLE  monoclonal rat antibody, hybridoma supernatant (clone 6E11), used 1:1000 in 
WB 
GFP  monoclonal mouse antibody (clone 3E6), used 1:400 in IF, purchased from 
Molecular Probes (Invitrogen) 
FLAG monoclonal mouse antibody, used 1:2000 in WB, purchased from Sigma 
H4K16ac polyclonal rabbit antibody, used 1:1000 in IF, purchased from Active Motif 
 
Secondary antibodies 
-rabbit HRP-conjugated    Amersham, GE Healthcare, Munich 
-mouse HRP-conjugated    Amersham, GE Healthcare, Munich 
-rat HRP-conjugated    Amersham, GE Healthcare, Munich 
donkey -rabbit IRDye 800-conjugated   Biomol, Hamburg 
donkey -mouse Alexa 488-conjugated  Invitrogen, Karlsruhe 
donkey -rabbit Cy3-conjugated   Invitrogen, Karlsruhe 
 
Secondary antibodies were diluted 1:10000 when used for WB and diluted 1:500 when used 
for IF. 
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4.1.4 Bacteria and cell lines 
E.coli BL21-CodonPlus (DE3)-RIL   Stratagene, La Jolla, CA, USA 
E.coli DH10Bac      Invitrogen, Karlsruhe 
E.coli XL1-Blue     Stratagene, La Jolla, CA, USA 
HEK-293 cells (human embryonic kidney)   provided by M. Eckey, P. Becker lab 
Sf21 cells (Spodoptera frugiperda)   Invitrogen 
SL2 cells (Drosophila melanogaster)   provided by T. Straub, P. Becker lab 
 
4.1.5 Dialysis, chromatographic and filtration material 
Amicon Ultra-4 Centrifugal Filter Devices  Millipore, MA, USA 
Anti-FLAG M2 Agarose from mouse  Sigma, Taufkirchen 
Chromatography systems (ÄKTA, FPLC)  GE Healthcare, Munich 
Gelfiltration column (Superose 6)   GE Healthcare, Munich 
Glutathione Sepharose 4B    GE Healthcare, Munich 
Micro Bio-Spin Chromatography Columns  Biozym, Hessisch Oldendorf 
SpectraPor dialysis membrane    Roth, Karlsruhe 
 
4.1.6 Kits and enzymes 
All enzymes were purchased from New England Biolabs (NEB, Frankfurt/Main). All 
Kits were purchased from Qiagen (Hilden), with exception of the Dual Luciferase Reporter 
Assay System from Promega (Mannheim) 
 
4.1.7 Oligonucleotides 
For EMSA, DNA oligonucleotides were synthesized by Biomers (Ulm), whereas 
RNA oligonucleotides were synthesized by metabion (Munich). For cloning, DNA 
oligonucleotides were synthesized by MWG (Munich). Crucial consensus sequences (for 
details see ‘results’ section), restriction sites or mutated bases are underlined. 
 
4.1.7.1 Oligonucleotides for EMSA 
DBF12-L15 DNA fw  5’- TGCGGCCATCTCTTTCGTTTTGATGTTTCTACGCCATGTG 
DBF12-L15 DNA rv  5’- CACATGGCGTAGAAACATCAAAACGAAAGAGATGG 
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DBF12-L18 DNA fw  5’- TGCGGCCAAAAAATTCGTTTTGATGTTTCTACGCCATGTG 
DBF12-L18 DNA rv  5’- CACATGGCGTAGAAACATCAAAACGAATTTTTTGG 
DBF12-L15 RNA fw  5’- UGCGGCCAUCUCUUUCGUUUUGAUGUUUCUACGCCAUGUG 
DBF12-L15 RNA rv  5’- CACAUGGCGUAGAAACAUCAAAACGAAAGAGAUGGCCGCA 
40TFO DNA fw  5’- TGCGGTCGAGGAAAAGAAAGAAAAAGGAAGCTCTTAGCGC 
40TFO DNA rv   5’- GCGCTAAGAGCTTCCTTTTTCTTTCTTTTCCTCGA 
27TFO DNA fw  5’- TGCGAGGAAAAGAAAGAAAAAGGAAGC 
27TFO DNA rv  5’- GCTTCCTTTTTCTTTCTTTTCCT 
21TFO-S RNA   5’- UCCUUUUCUUUCUUUUUCCUU 
16TFO-L15 RNA  5’- UUUUCCUUUCUCUCCC 
UAS consensus DNA fw 5’- AGGTCGGAGGACTGTCCTCCGAGGT 
UAS consensus DNA rv  5’- ACCTCGGAGGACAGTCCTCCG 
UAS mutated DNA fw 5’- AGGTCCGAGGACTGTCCTCGGAGGT 
UAS mutated DNA rv  5’- ACCTCCGAGGACAGTCCTCGG 
 
4.1.7.2 Oligonucleotides for cloning and site-directed mutagenesis 
Oligonucleotide name Sequence from 5’ to 3’ Description 
RING SalI fw ACGCGTCGACATGCCTC
GCATCAAGCTG 
forward primer with SalI restriction 
site to clone MSL2-RING into 
pFastBac1 
MSL2 SalI fw ACGCGTCGACATGGCCC
AGACGGCATAC 
forward primer with SalI restriction 
site to clone MSL2-CXC and 
MSL2-Pro/Bas into pFastBac1 
MSL2 FLAG NotI rv GATTGCGGCCGCTTACT
TATCGTCGTCATCCTTG
TAATCCAAGTCATCCGA
GCCCGA 
reverse primer with NotI restriction 
site and cds for FLAG peptide to 
clone MSL2-RING and CXC into 
pFastBac1 
Pro/Bas FLAG NotI 
rv 
GATTGCGGCCGCTTACT
TATCGTCGTCATCCTTG
TAATCGAAGATGATATT
GAAGCCCTG 
reverse primer with NotI restriction 
site and cds for FLAG peptide to 
clone MSL2-Pro/Bas into 
pFastBac1 
MSL2 KpnI fw CGGGGTACCATGGCCCA
GACGGCATAC 
forward primer with KpnI restriction 
site to clone MSL2-Pro/Bas into 
pVP16 
Pro/Bas AgeI rv CGCGACCGGTGGGAAGA
TATTGAAGCCCTG 
reverse primer with AgeI restriction 
site to clone MSL2-Pro/Bas into 
pVP16 
HsCXC PacI fw CCTTAATTAAGCCGAAG
TGTAAATGTGGGCGTGC
forward primer with PacI restriction 
site to clone HsCXC domain into 
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TA pFastBac1 and pVP16 
HsCXC NheI rv CTAGCTAGCCGGATTCT
TGCAGCCACGACATATA
CAA 
reverse primer with NheI restriction 
site to clone HsCXC domain into 
pFastBac1 and pVP16 
MSL2 vect elong PacI 
fw 
GGTTAATTAACGGAGGC
TTCACCTTTTC 
forward primer to exclude CXC 
domain and to introduce PacI 
restriction site into pFastBac1-
MSL2 and pVP16-MSL2 vectors 
MSL2 vect elong NheI 
rv 
CTAGCTAGCCACAAGGA
GGACTACGTTG 
reverse primer to exclude CXC 
domain and to introduce NheI 
restriction site into pFastBac1-
MSL2 and pVP16-MSL2 vectors 
mut CC to AA fw CCTGCCGGAATTCCCGA
GCTCCTGCCTACAAGAG
TTACAACAG 
forward primer to change aa C544A 
and C546A by site-directed 
mutagenesis 
mut CC to AA rv CTGTTGTAACTCTTGTA
GGCAGGAGCTCGGGAAT
TCCGGCAGG 
reversse primer to change aa C544A 
and C546A by site-directed 
mutagenesis 
mut Y to A fw AATTCCCGATGTCCTTG
CGCCAAGAGTTACAACA
GCTGT 
forward primer to change aa Y547A 
by site-directed mutagenesis 
mut Y to A rv ACAGCTGTTGTAACTCT
TGGCGCAAGGACATCGG
GAATT 
reverse primer to change aa Y547A 
by site-directed mutagenesis 
 
4.1.8 Plasmids 
Details of the cloning procedure for the individual plasmids can be found in the 
‘cloning of expression constructs’ section. 
Plasmid name Description Generated by 
pFastBac1-MSL2-
FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-FLAG in Sf21 cells 
T. Fauth 
pFastBac1-MSL2-
RING-FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-RING-FLAG in Sf21 cells 
T.Fauth 
pFastBac1-MSL2-
CXC-FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-CXC-FLAG in Sf21 cells 
T.Fauth 
pFastBac1-MSL2-
Pro/Bas-FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-Pro/Bas-FLAG in Sf21 cells 
T.Fauth 
pFastBac1-MSL2-
HsCXC-FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-HsCXC-FLAG in Sf21 cells 
T.Fauth 
pFastBac1-MSL2-
C544A/C546A-
FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-C544A/C546A-FLAG in Sf21 
cells 
T.Fauth 
pFastBac1-MSL2-
Y547A-FLAG 
used to create recombinant Baculovirus for 
expression of MSL2-Y547A-FLAG in Sf21 cells 
T.Fauth 
pFastBac1-CXC-
FLAG 
used to create recombinant Baculovirus for 
expression of CXC-FLAG in Sf21 cells 
T.Fauth 
pFastBac1-MSL1- used to create recombinant Baculovirus for T.Fauth 
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FLAG expression of MSL1-FLAG in Sf21 cells 
pFastBac1-MSL1 
 
used to create recombinant Baculovirus for 
expression of untagged MSL1 in Sf21 cells 
V. Morales 
pcDNA3.1-MSL2-
VP16 
expression of MSL2-VP16 in mammalian cells T. Fauth 
pcDNA3.1-MSL2-
CXC-VP16 
expression of MSL2-CXC-VP16 in mammalian 
cells 
T. Fauth 
pcDNA3.1-MSL1-
VP16 
expression of MSL1-VP16 in mammalian cells T. Fauth 
pEGFP-N2 expression of GFP in mammalian cells BD Biosciences  
pVP16 expression of VP16 activation domain in SL2 cells Clontech 
pMSL2-VP16 expression of MSL2-VP16 in SL2 cells C. König 
pMSL2-RING-
VP16 
expression of MSL2-RING-VP16 in SL2 cells C. König 
pMSL2-CXC-
VP16 
expression of MSL2-CXC-VP16 in SL2 cells C. König 
pMSL2-Pro/Bas-
VP16 
expression of MSL2-Pro/Bas-VP16 in SL2 cells T. Fauth 
pMSL2-HsCXC-
VP16 
expression of MSL2-HsCXC-VP16 in SL2 cells T. Fauth 
pMSL2-
C544A/C546A-
VP16 
expression of MSL2-C544A/C547A-VP16 in SL2 
cells 
T. Fauth 
pMSL2-Y547A-
VP16 
expression of MSL2-Y547A-VP16 in SL2 cells T. Fauth 
pGL3-TK-
Luc_mod 
 
inducible firefly luciferase reporter  C. König 
pRL-TK ‘Renilla’ 
 
constitutive Renilla luciferase reporter Promega 
pGL3-DBF12-L15 
 
DBF12-L15 binding site upstream of firefly 
luciferase reporter 
C. König 
pGL3-DBF12-L18 
 
DBF12-L18 binding site upstream of firefly 
luciferase reporter 
C. König 
pGL3-3xDBF12-
L15 
Trimerized DBF12-L15 binding site upstream of 
firefly luciferase reporter 
C. König 
pGL3-roX1DHS DHS of roX1 upstream of firefly luciferase reporter C. König 
pBluescript KS+ mcs of varying length was used in EMSA Stratagene 
pP12eL(15)3 pCASPER vector with 3 copies of the DBF12-L15 
binding site. 167 bp fragment was used in EMSA 
I. Dahlsveen 
pUCA-roX1-DHS 
short 
pUC vector with roX1-DHS binding site. 226 bp 
fragment was used in EMSA  
G. Mengus 
pGEX-2KG inducible expression of GST in E.coli Amersham 
pGEX-2KG-CXC inducible expression of GST-CXC in E.coli T. Fauth 
pEGFP-hsp-MSL2 
 
used for expression of GFP-MSL2 in a stable SL2 
cell line 
T. Straub 
pEGFP-hsp-
MSL2-CXC 
used for expression of GFP-CXC in a stable SL2 
cell line 
T. Straub 
pEGFP-MSL2- used for expression of GFP-C544A/C547A in a T. Fauth 
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hsp-C544A/C547A stable SL2 cell line 
pY3-Gal4-MOF-
FLAG 
used for expression of MOF-Gal4DBD-FLAG from 
its endogenous promoter in a stable SL2 cell line 
M. Prestel 
pY3-w/oGal4-
MOF-FLAG 
used for expression of MOF-FLAG from its 
endogenous promoter in a stable SL2 cell line 
T. Fauth 
pCoBlast selection vector carrying Blasticidin resistance to 
create stable SL2 cell lines 
Invitrogen 
 
4.1.9 Baculoviruses 
Recombinant baculoviruses were created by using pFastBac1 vectors (see section 
above) and the Bac-to-Bac expression system (Invitrogen). Amplification and maintenance of 
viruses was performed according to the manufacture’s instructions (Invitrogen). All 
baculoviruses were created within this study, with the exception of the MSL1 (untagged) 
baculovirus, which was created by V. Morales [75]. 
 
4.1.10 Other materials 
DE81 anion exchanger chromatography   Whatman, Dassel 
paper  
ECL detection system     GE Healthcare, Munich 
Immobilon-P PVDF membrane   Millipore, MA, USA 
Nitrocellulose membrane    Whatman, Dassel 
Polystyrene tubes, 5 ml, 75 x 12 mm   Sarstedt, Nümbrecht 
Protein marker      Peqlab Biotechnologie, Erlangen 
Siliconised reaction tubes, 1.5 ml   Biozym, Hessisch Oldendorf  
Super RX Fuji medical X-ray film   Fuji, Düsseldorf 
Whatman 3MM paper     Whatman, Dassel 
 
4.1.11 Standard buffers 
Standard buffers are listed below, whereas additional buffers are described in the 
individual ‘methods’ sections. 
LB media / agar plates:  1% (w/v) Peptone 
     0.5% (w/v) Yeast extract 
     1% (w/v) NaCl 
     for LB agar plates 2% (w/v) agar was added  
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SDS-PAGE Loading Buffer (4x):  0.5 M   Tris / HCl pH 6.8 
     4% (v/v)  SDS 
     0.08% (w/v)  Bromphenol Blue 
     40% (v/v)  Glycerol 
     1.144 M  -Mercaptoethanol 
 
SDS-PAGE Running Buffer:  25 mM  Tris 
     192 mM  Glycine 
     0.1% (w/v) SDS 
 
PBS:     137 mM NaCl 
     2.7 mM KCl 
     10 mM  Na2HPO4 x 12 H2O 
     2.0 mM  KH2PO4 
 
TBE:     90 mM  Tris base 
     90 mM  Boric acid 
2 mM   EDTA 
 
4.2 Mammalian and insect tissue culture 
4.2.1 General cell culture conditions  
Tissue culture work was performed under sterile conditions. All solutions were 
preheated before use either to 37°C when used for human cells or to RT when used for insect 
cells. To determine the cell number, cells were first mixed with the same volume of Trypan 
Blue to stain dead cells and then counted in a hemacytometer. 
 
4.2.2 Cultivation of human HEK-293 cells 
The human embryonic kidney cell line HEK-293 was kindly provided by M. Eckey 
(P. Becker lab). HEK-293 cells were kept in DMEM Medium (see section ‘chemicals for 
tissue culture’) supplemented with 9% (v/v) FBS in 25 cm2-flasks at 37°C and 5% CO2. 
When cells reached confluency, cells were detached by carefully pipetting up and down and 
diluted again in 7 ml fresh medium to 0.5 x 106 cells.  
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4.2.3 Cultivation of Spodoptera frugiperda Sf21 cells 
Sf21 cells were cultured in Sf-900 II SFM that was supplemented with 9 mg/ml 
gentamycin and 9% (v/v) FBS. Cells were grown in 1L-shaker flasks in 100 - 300 ml medium 
at 27°C and 75 rpm. The cell density was kept between 0.5 x 106 and 4.0 x 106 cells/ml, thus 
cells stay in the exponential growth phase. 
 
4.2.4 Cultivation of Drosophila melanogaster SL2 cells 
SL2 cells were cultured at 26°C in Schneider’s Drosophila medium (Invitrogen) 
containing L-glutamine and additionally supplemented with penicillin, streptomycin and 9% 
(v/v) FBS. Cells were kept in 75 cm2-flasks in 20 ml medium between 0.5 x 106 and 4.0 x 106 
cells/ml, in order to keep cells exponentially growing. 
 
4.2.5 Freezing and thawing of SL2 cells 
 The SL2 cells must be diluted to around 1.5 x 106 cells/ml in a 75 cm2-flask two days 
prior freezing. Then cells were centrifuged at 500 g for 4 min at RT and carefully resuspended 
in 3 ml Freezing Medium (60% (v/v) FBS, 10% (v/v) DMSO, 30% (v/v) medium). 0.5 ml 
aliquots were made, stored first for 30 min at -20°C then stored overnight at -80°C.  For long-
term storage, cells were kept in liquid nitrogen. A frozen stock was thawed rapidly in hand 
and quickly transferred in 10 ml fresh medium to dilute the toxic DMSO. Cells were 
centrifuged as above, resuspended in 7 ml medium and transferred to a small flask (25 cm2). 
Further cultivation was performed as described above. 
 
4.2.6 Generation of stable SL2 cell lines 
Stable SL2 cell lines were generated by cotransfection of the pCoBlast selection 
vector and the expression vector. In SL2 cells vectors are generally integrated as multicopies 
that form arrays of more than 500 - 1000 copies in a head to tail fashion (Invitrogen manual). 
0.5 x 106 cells were seeded in a 6 well plate containing 2 ml fresh medium and incubated as 
described above. The next day 20 ng of pCoBlast and 400 ng of the expression vector were 
transfected into SL2 cells using the Effectene reagent (Qiagen). First the vectors were mixed 
in 100 l EC Buffer (Qiagen), then 3.2 l of Enhancer Solution (Qiagen) was added and 
vortexed for 1 sec. After incubation for 5 min at RT 10 l Effectene Reagent was added, 
vortexed for 10 sec and again incubated for 10 min at RT. Finally 0.6 ml fresh medium was 
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mixed with the DNA-transfection mix and slowly added to 1 x 106 cells in 1.6 ml fresh 
medium per 6-well. After 24 h the transfection mix was removed and 3 ml blasticidin 
containing medium was added (25 ng/l). The procedure was repeated after further 2, 5 and 
10 days, when the stable cells grow out. Within the next one or two weeks resistant cells were 
transferred together with the conditioned and additional fresh blasticidin containing medium 
to small flasks (25 cm2, 7 ml total volume). Before transferring to 75cm2-flasks cells were 
centrifuged as above to remove dead cells. Then the stable cell line was routinely kept in 75 
cm2-flasks, under constant selection (20 ng/l blasticidin).  
 
4.3 Methods for manipulation of DNA 
4.3.1 General molecular biology methods  
Molecular biology methods that deal with the analysis and manipulation of nucleic 
acids were performed according to standard (Laboratory Manuals from Sambrook and 
Russell) and manufacturer’s protocols (New England Biolabs). This includes concentration 
determination of nucleic acids, restriction enzyme digestion and ligation of DNA fragments, 
analysis of DNA on agarose gels and amplification of DNA fragments by polymerase chain 
reaction (PCR). In addition preparation of chemically competent and transformation of E.coli 
cells were performed as described in [189]. Plasmid DNA was prepared by using the Qiagen 
Midi or Maxi Kit. For isolation of DNA fragments from agarose gels and for clean-up of 
enzymatic reactions the QIAquick Gel Extraction Kit and the QIAquick PCR Purifiction Kit 
(both Qiagen) were used respectively. 
 
4.3.2 Cloning of expression constructs 
For expression in Sf21 cells, the different MSL2-FLAG constructs were cloned into 
the pFastBac1 vector by using the SalI/NotI restriction sites, either by subcloning or by 
introducing the SalI/NotI restriction sites via PCR with primers that contain the corresponding 
restriction sites, whereby the primer with the NotI restriction site contained in addition the cds 
for the FLAG-tag.  
For cloning MSL1 into pFastBac1 vector, the MSL1-FLAG cds was first cut out from 
the existing pGSC-URA vector using NotI/PacI (blunt) restriction enzymes and then 
subcloned into the NotI/XbaI (blunt) sites. 
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The chimeric MSL2 construct was created by first simultaneously removing the 
DmCXC domain from the wildtype MSL2 cds (within the pFastBac1 and pVP16 vector) and 
introducing PacI/NheI restriction sites via inverse PCR. These restriction sites were then used 
to insert the HsCXC domain, which was amplified from cDNA of HeLa cells via PCR using 
primers that include PacI/NheI restriction sites.  
For expression in HEK-293 cells, the different MSL constructs were subcloned into 
the pcDNA3.1 vector from already existing pMSL-VP16 vectors using KpnI/NotI restriction 
sites.  
For expression in SL2 cells, all MSL constructs had been previously cloned into 
pVP16 plasmids (C. König, P. Becker lab), except the MSL2-Pro/Bas construct, which was 
subcloned by using KpnI/AgeI restriction sites. 
  For immunofluorescence stainings on SL2 cells, all MSL constructs had been 
previously cloned into the pEGFP vector (T. Straub, P. Becker lab), except the MSL2 
construct containing double point mutations (MSL2-C544A/C546A), which was created by 
subcloning a small fragment containing the point mutations using PflMI/BstEII restriction 
enzymes.  
 For bacterial expression as a GST fusion protein, the sequence of the CXC domain 
was amplified by PCR using primers that contain XmaI/SacI restriction sites and 
subsequently cloned into XmaI/SacI restriction sites of the pGEX-2KG vector. 
 For creating the MOF-FLAG construct, the already existing MOF-Gal4DBD construct 
(M. Prestel, P. Becker lab) was digested with RsrII to remove the Gal4DBD and then was 
religated again. 
 Details of the composition of the individual primers can be found above in the 
‘oligonucleotides’ section. The correctness of all constructs was verified by sequencing. 
 
4.3.3 Site-directed mutagenesis  
Specific mutations were introduced into the DNA sequence by site-directed 
mutagenesis following the manufacturer’s instructions (QuickChange Kit, Stratagene). The 
designed primers carrying the changed base triplets are listed above in the ‘oligonucleotides’ 
section. 
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4.3.4 Preparation of long DNA fragments 
The trimerized DBF12-L15 DNA element (167 bp) and a control DNA fragment of 
similar length (170 bp) was obtained by restriction digestion of pP12eL(15)3 vector with 
BamHI/XhoI or of pBluescript KS+ vector with PvuII/XmaI respectively. The roX1-DHS 
DNA fragment (226 bp) and a control DNA fragment of similar length (225 bp) was obtained 
by restriction digestion of pUCA-roX1DHS-short plasmid with AvaI or of pBluescript KS+ 
plasmid with AvaII respectively. The DNA fragments were then purified from Agarose-gels 
using the Qiagen Gel extraction Kit, further concentrated by EtOH precipitation and finally 
resolved in ddH2O and stored at -20°C. Since restriction digestion of all plasmids created a 
5’-overhang, the overhanging ends were filled-in with radioactive dCTP by the Klenow 
enzyme.  
 
4.3.5 Annealing of oligonucleotides 
Double stranded oligonucleotides were created by mixing equimolar concentrations 
(10 M) of the sense and the anti-sense strands in Annealing Buffer (10 mM Tris/HCl pH 7.5, 
50 mM NaCl, 0.1 mM EDTA). Both strands were annealed by heating for 5 min at 95°C 
followed by gradually cooling down to RT. Finally, the double stranded oligonucleotides 
were stored in small aliquots at -20°C.  
 
4.3.6 Radioactive labeling of DNA fragments 
DNA fragments were radioactively labeled by fill-in of overhanging ends using the 
Klenow enzyme. 5’-overhangs of DNA fragments were created either by annealing of the 
sense and a shorter anti-sense strand or by restriction digestion of plasmid DNA (see sections 
above). The 5’-overhangs were then filled-in by the Klenow fragment of DNA-Polymerase I 
in the presence of radioactive [-32P]-dCTP and non-radioactive dNTPs. 5 pmol of DNA and 
5 U of the Klenow fragment were incubated for 15 min at 25°C with non-limiting amounts of 
[-32P]-dCTP (10 mCi/ml, 3000 Ci/mmol), non-radioactive dATP, dGTP, dTTP (100 M 
each) in NEB Buffer 2 in a final volume of 50 l.  
In contrast to DNA, RNA oligonucleotides were labeled at their 5’-ends using T4-
Polynucleotide Kinase (T4-PNK). Since the RNA oligonucleotides were synthesized without 
a phosphate group at their 5’-ends, it was not necessary to dephosphorylate the ends prior to 
the kinase reaction. 20 pmol of double stranded RNA and 20 U of T4-PNK were incubated 
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for 1 h at 37°C with 75 pmol, which is a non-limiting amount, of [-32P]-dATP (150 mCi/ml, 
6000 Ci/mmol) in T4-PNK Buffer (New England Biolabs) in a final volume of 20 l. 
After the labeling reactions, radiolabeled DNA and RNA were purified using the QIAquick 
Nucleotide Removal Kit (Qiagen) according to the manufacture’s protocol. The purified 
radiolabeled DNA and RNA were finally eluted with 100 l buffer (10 mM Tris/HCl pH 8.0), 
measured in a scintillation counter (Beckman LS 1801) and stored in aliquots at -20°C. 
 
4.3.7 Formation of RNA-DNA triplexes 
The RNA-DNA triplexes were formed by incubating unlabeled single stranded RNA 
(varying amounts, see results section) and radiolabeled DNA duplex (0.1 - 0.4 nM, 6000 - 
10000 cpm) in Triplex Formation Buffer (50 mM MOPS/NaOH pH 7.4, 200 nM spermidine 
trihydrochloride, 5% (v/v) glycerol) for 15 min at 25°C. The triplex formation was then 
controlled by separating duplex and triplex structures in native PAA gels (50 mM 
MOPS/NaOH pH 7.4, 5% (v/v) polyacrylamide solution (37.5:1), 0.05% (v/v) TEMED, 0.1% 
(v/v) APS, 6 mM MgCl2) at 4°C in 6 mM MgCl2 containing MOPS buffer (50 mM). The gels 
were pre-electrophoresed at 110 V for 30 min at RT and, subsequently, the triplex and duplex 
structures were separated at 120 V at 4°C. Gels were dried on anion exchanger 
chromatography and Whatman paper and radiolabeled nucleic acids were visualized by using 
a Phosphor-Imager (FujiFilm FLA-3000). 
 
4.4 Methods for protein analysis  
4.4.1 Precipitation of proteins with Trichloroacetic acid (TCA) 
In order to obtain higher concentrated samples for SDS-PAGE protein samples were 
mixed with TCA (20% (v/v) final concentration) and incubated for at least 10 min on ice. 
After centrifugation at 13,000 rpm for 30 min at 4°C the protein precipitate was washed twice 
with ice-cold acetone. The protein pellet was air-dried, then dissolved in an appropriate 
volume of 8 M urea and 2 x SDS-PAGE Loading Buffer. Before subjected to SDS-PAGE, 
protein samples were boiled for 5 min at 95°C. 
 
4.4.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 Separation of proteins by SDS-PAGE was performed in the Novex Mini-Cell system 
(Invitrogen). Resolving and stacking gels were poured according to the manufacture’s 
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instructions using 30% (v/v) polyacrylamide solution (Rotigel, 37.5:1 acrylamide to 
bisacrylamide) and resolving gel buffer (375 mM Tris/HCl pH 8.8) or stocking gel buffer 
(125 mM Tris/HCl pH 6.8) respectively. Prior to loading samples were mixed with SDS-
PAGE Loading Buffer and heat-denatured for 5 min at 95°C. Various molecular weight 
protein standards were purchased from Bio-Rad. Electrophoresis was performed at 40 - 80 
mA at RT for varying time. Afterwards SDS-PAA gels were either used for Coomassie 
staining, silver staining or Western blotting.  
 
4.4.3 Silver staining of protein gels 
 All steps were performed in a clean, round glass container. The SDS-PAA gel was 
first briefly rinsed in ddH2O and proteins fixed by incubation for 15 min in 50% MeOH, 
followed by a second incubation for 15 min in 5% MeOH. The gel was briefly rinsed in 
ddH2O before gentle swirling for 15 min in Reducing Solution (32 M DTT). It followed a 
two times rinsing step for 10 sec in ddH2O and a short 10 sec preincubation followed by 15 
min incubation (swirling) in Silver Stain Solution (0.1% (w/v) AgNO3). The gel was again 
rinsed twice for 10 sec in ddH2O before a short 10 sec preincubation in a small volume of 
Developer Solution (3% (w/v) Na2CO3, 0.05% (v/v) formaldehyde). Developer Solution was 
added again, the gel was swirled gently and the staining process was followed until the 
desired color intensity was reached. The reaction was stopped by adding solid Citric acid 
monohydrate until gas formation ceases. The gel was incubated for a few more minutes 
before it was swirled and stored in ddH2O. Finally the gel was scanned. 
 
4.4.4 Staining of protein gels by Coomassie Blue 
After separation by SDS-PAGE, proteins were at the same time fixed and stained by 
incubating the polyacrylamide gel in Fixation-Staining Solution (40% (v/v) EtOH, 10% (v/v) 
acetic acid, 0.62 g (w/v) Coomassie G-250). After 1 h shaking at RT, the protein gel was 
transferred into Destain Solution (10% (v/v) acetic acid) and shaken at RT until protein bands 
became visible. The destained protein gel was either used for quantification or identification 
of protein bands (by mass spectrometry), before it was finally dried on a Whatman paper at 
80°C for 1 h on a gel dryer (BioRad). 
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4.4.5 Determination of protein concentration 
For quantitative experiments (e.g. measuring affinity constants with EMSAs) the 
concentration of the purified recombinant protein must be exactly determined. Therefore the 
recombinant protein was resolved from other eventually co-purified proteins by SDS-PAGE, 
then visualized by Coomassie staining and finally quantified by densitometry (Odyssey 
Infrared Imaging System, LI-COR Biosciences). The protein concentration was then 
determined by comparing the measured intensity of the protein band and the measured 
intensities of a standard curve, which was created by titration of known amounts of BSA 
(purchased from New England Biolabs).  
 
4.4.6 Protein transfer to membranes (Western blot) 
The transfer of proteins, which were separated by SDS-PAGE, from the 
polyacrylamide gel to a PVDF membrane, was achieved with a semidry transfer cell (Trans-
Blot SD, Bio-Rad). Before the transfer, the polyacrylamide gel and the PVDF membrane 
(after its activation in MeOH and rinsing in ddH2O) or nitrocellulose membrane were 
equilibrated in Cathode Buffer and Anode Buffer II respectively. The blot was then 
assembled the following way (from anode to cathode): 2 Whatman papers soaked in Anode 
Buffer I (300 mM Tris/HCl pH 7.5, 20% (v/v) MeOH), 1 Whatman paper soaked in Anode 
Buffer II (25 mM Tris/HCl pH 7.5, 20% (v/v) MeOH), membrane, polyacrylamide gel and 
finally 4 Whatman papers soaked in Cathode Buffer (70 mM CAPS pH 10.5, 10% (v/v) 
MeOH). The Transfer was performed at 0.8 mA/cm2 membrane for either 1.5 h (7.5% 
polyacrylamide gel) or 2 h (10% polyacrylamide gel). Afterwards the nitrocellulose 
membrane was directly used for immunodetection, whereas the PVDF membrane was air-
dried and stored at RT until further use for immunodetection. 
 
4.4.7 Immunodetection of transferred proteins 
The membranes were incubated in Blocking Buffer (1 x PBS, 0.05% (v/v) Tween 20, 
3 - 5% (w/v) milk powder) for 1 h at RT in order to saturate free binding sites on the 
membrane and hence minimize the non-specific background. Since the PVDF membrane was 
dried after the Western blot, it has to be activated again in MeOH and rinsed in dH2O before 
putting into the Blocking Buffer. After blocking the membranes were incubated either for 1 h 
at RT or o/n at 4°C with an appropriate dilution of the primary antibody. Before and after the 
incubation for an additional hour with horseradish peroxidase (HRP)- or infrared (IR) dye-
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coupled secondary antibody, the membranes were extensively washed for several times in 
PBS-T Buffer (1 x PBS, 0.05% (v/v) Tween 20). Finally, the antigen-antibody complexes 
were detected by chemoluminescence using the ECL detection system (GE Healthcare) and 
autoradiography. After a variable exposure time the X ray films were developed and the 
autoradiograph was scanned. Alternatively, when secondary antibodies that are coupled to an 
IR dye were used proteins were detected by using the Odyssesy Infrared Imaging System (LI-
COR Biosciences). 
 
4.4.8 Superose 6 gelfiltration of purified MSL proteins 
The stoichiometry and composition of the recombinant MSL2 protein and of the 
purified MSL2-MSL1 complex was analyzed by chromatographic gel filtration using the Äkta 
FPLC system (Amersham pharmacia). Chromatography runs were carried out at 4°C, all 
solutions were filtered (0.22 m pore size) and chilled to 4°C. The Superose 6 column (20 ml 
CV) was washed with ddH2O before it was equilibrated in Elution Buffer (100 mM KCl for 
MSL2 and 300 mM KCl for MSL2-MSL1). Purified protein solutions that were used for gel 
filtration did not contain NP-40, but were reduced by adding DTT (1 mM). Before loading 
onto the equilibrated Superose 6 column the protein solution was centrifuged at 13,000 g for 
15 min at 4°C to remove protein aggregates. Around 60 g of the protein solution in 250 l 
was loaded onto the column and 500 l fractions were collected at a flow-rate of 0.5 ml/min 
(pressure limit 1.5 MPa). Protein fractions were precipitated with TCA and analyzed by SDS-
PAGE and Coomassie staining. 
 
Elution Buffer: 50 mM Hepes/KOH pH 7.6 
100 mM or 300 mM KCl 
5% (v/v) Glycerol 
1 mM MgCl2 
0.5 mM EDTA 
5 mM DTT 
 
4.4.9 Mass spectrometry 
Mass spectrometry analysis was performed by the ZfP (‘Zentrum für Proteinanalytik’, 
Adolf-Butenandt-Institute, LMU) according to the following protocol. Cut gel slices from 
SDS-PAGE were washed twice with water and twice with 40 mM ammoniumbicarbonate 
Materials and Methods                                                                                                             87 
each for 30 min. After two-times treatment with 50% acetonitrile for 5 min, trypsin 
(Sequencing Grade Modified, Promega) was added and proteins were digested overnight in 
40 mM ammoniumbicarbonate at 37°C while shaking (600 rpm). For protein identification 
probes/peptides were first purified (desalted) using C18 ZipTips (Millipore) and then used for 
nano-ESI-LC-MS/MS. Each sample was first separated on a C18 reversed phase column (75 
m i.d. x 15 cm, packed with C18 PepMap, 3 m, 100 Å) by LC Packings via a linear 
acetonitrile gradient. MS and MS/MS spectra were recorded on an Oribitrap mass 
spectrometer (Thermo Electron). The resulting spectra where then analyzed via the Mascot 
Software (Matrix Science) using the NCBInr Protein Database. 
 
4.5 Expression and purification of proteins and protein complexes 
4.5.1 Heterologous expression of MSL proteins in insect Sf21 cells 
4.5.1.1 Infection of Sf21 cells with baculoviruses 
MSL proteins were expressed in Sf21 cells using recombinant baculoviruses. 
Wildtype MSL2 and MSL1, as well as all truncated or mutated MSL2 versions contained C-
terminal FLAG-tags. In the coexpressed MSL2-MSL1 complex only MSL2 was FLAG-
tagged, MSL1 was untagged. Baculovirus infections were usually carried out in shaker flasks 
(1 x 106 cells/ml, 250 ml) with the optimal amount for each virus, which was determined 
before in test expressions. After 2 days of expression using the same conditions as described 
above cells were harvested, the cell pellet washed with ice-cold PBS, frozen in liquid nitrogen 
and stored at -80°C until preparation of cell extracts. 
 
4.5.1.2 Preparation of Sf21 cell extracts 
Sf1 cell pellets, which were stored at - 80°C, were rapidly thawed in a water bath at RT and 
then put on ice immediately. Per 5 ml PCV 15 ml ice-cold Lysis Buffer was added and cells 
completely resuspended. After 10 min incubation on ice and occasional mixing, cells were 
lysed by sonication (4 x 10 sec pulses with 20% Amplitude = 6 Watt and 20 sec pause, 
Branson Digital Sonifier 250D) under constant cooling in ice water. Cell debris and insoluble 
proteins were removed by centrifugating the cell lysate twice – one time for 30 min and a 
second time for 15 min at 30,000 g and 4°C. The supernatant represents the soluble protein 
fraction, which is directly used for further protein purification. 
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Lysis Buffer:  50 mM Hepes/KOH pH 7.6 
300 mM KCl 
5% (v/v) Glycerol 
0.05% (v/v) NP-40 
1 mM MgCl2 
0.5 mM EDTA 
Protease inhibitors (Aprotinin 1 g/ml, Leupeptin 1 g/ml and 
Pepstatin 0.7 g/ml) were added just before use 
 
4.5.1.3 Purification of FLAG-tagged MSL proteins from Sf21 cell extracts 
The soluble protein fraction was incubated with in chilled Lysis Buffer equilibrated FLAG 
beads (Anti-FLAG M2 Agarose, Sigma) for 2.5 h at 4°C on a rotating wheel, whereby 250 l 
beads (which equals 500 l original slurry) were used per 5 ml PCV. All subsequent washing 
steps were carried out with ice-cold and at least 10 ml of buffer. The beads were washed 
briefly with Lysis Buffer, followed by a second wash step on the rotating wheel for 5 min. In 
order to reduce non-specific interactions with the beads and with the FLAG-tagged proteins, 
another washing step for 10 min on a rotating wheel with high-salt (1 M) was added. It 
follows a quick wash with lower salt 300 mM KCl and two quick washes in Elution Buffer. 
The FLAG-tagged MSL proteins were then eluted for 2.5 h at 4°C on a rotating wheel in the 
presence of 0.5 mg/ml FLAG-Peptide (Sigma) in a total volume of 900 l per 250 l beads. 
The Elution Buffer contained either 100 mM KCl for MSL2 or 300 mM KCl for MSL1 and 
the MSL2-MSL1 complex. The eluted proteins were seperated from FLAG-beads by short 
centrifugation through Micro Bio-Spin columns (Bio Rad) and were further concentrated by 
centrifugation at 3000 rpm using Amicon Ultra-4 centrifugal filter devices (50 kDa or 3 kDa 
exclusion limit, Millipore). Purified proteins were then rapidly frozen as small aliquots (10 - 
20 l) in liquid nitrogen and finally stored at -80°C.  
 
Elution Buffer:  composition as Lysis Buffer  
but containing either 100 mM or 300 mM KCl 
 
Materials and Methods                                                                                                             89 
4.5.2 Bacterial expression of the GST-tagged CXC domain 
4.5.2.1 Induction of protein expression 
E.coli BL21-CodonPlus cells were transformed with the pGEX-2KG-GST-CXC 
vector, which allows upon induction by IPTG the expression of the isolated CXC domain 
fused to a GST-tag. A 200 ml preculture, which grew overnight at 22°C and 200 rpm, was 
used to inoculate a 2 L expression culture (OD600 = 0.1). Cells were grown at 20°C and 200 
rpm under constant selection pressure in LB-Amp-Cam medium. When cell density reached 
OD600 = 0.7 - 0.8 expression was induced with 0.3 mM IPTG and lasted for 2 h. Cells were 
then harvested by centrifugation for 15 min at 4000 g at 4°C and washed once with PBS. The 
bacterial cell pellet was frozen in liquid nitrogen and stored at -80°C until extract preparation. 
 
4.5.2.2 Preparation of bacterial cell extract  
 The bacterial cell pellet was rapidly thawed and resuspended in 30 ml ice-cold 
Extraction Buffer per 5 ml PCV. Cells were lysed by using the French Press (2 x 1500 psi) 
and by sonication (3 x 10 sec pulses with 25% Amplitude = 7 Watts and 30 sec pause, 
Branson Digital Sonifier 250D) under constant cooling in ice water. Cell debris and insoluble 
proteins were removed by centrifugating the cell lysate for 30 min at 30,000 g and 4°C. The 
supernatant represents the soluble protein fraction, which is directly used for further protein 
purification. 
 
Extraction Buffer: 1 x PBS 
   0.36 M NaCl 
   0.05% (v/v) NP-40 
   1 mM DTT 
   50 M ZnCl2 
   1 mM PMSF 
Protease inhibitors (Aprotinin 1 g/ml, Leupeptin 1 g/ml, Pepstatin 
0.7 g/ml), DTT and PMSF were added prior to usage 
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4.5.2.3 Purification of GST-tagged CXC domain from bacterial cell extracts 
The bacterial protein extract was allowed to enter the packed material of a custom-
made affinity column consisting of around 300 l of loosely packed Glutathione Sepharose 
(GE Healthcare), which was equilibrated with ice-cold Extraction Buffer (without ZnCl2 and 
PMSF), by gravity flow. After passing through the column the protein extract was applied 
several times again. Afterwards the column was washed with Extraction Buffer, followed by a 
high-salt wash in 1 M salt and another wash in Extraction Buffer. The column was then 
equilibrated with Elution Buffer and GST-tagged protein was eluted from the column by 
incubating the column for 2 h at 4°C in the presence of 40 mM glutathione with 1.3 x CV of 
Elution Buffer. Finally the eluted protein is collected from the column by adding another 1.3 
x CV of Elution Buffer containing 40 mM glutathione. Aliquots of the eluted protein were 
quickly frozen in liquid nitrogen and stored at -80°C.  
 
Elution Buffer: 200 mM Tris/HCl pH 8.0 
   10% (v/v) Glycerol 
   150 mM NaCl 
   0.05% (v/v) NP-40 
   1 mM DTT 
Protease inhibitors (Aprotinin 1 g/ml, Leupeptin 1 g/ml, Pepstatin 
0.7 g/ml) and DTT were added prior to usage 
 
4.5.3 Enrichment of native MOF containing fractions from SL2 cells 
4.5.3.1 Preparation of nuclear extracts from SL2 cells 
Nuclear extracts were prepared according to a protocol developed by Andreas 
Hochheimer (B.R.A.I.N. AG, Zwingenberg, Germany), which is based on two already 
published protocols [190, 191]. SL2 cell culture was expanded from a 75cm2-flask to several 
roller bottles (maximum 400 ml) and a final concentration of 2 - 3 x 106 cells/ml. Cells were 
harvested at 1300 g for 15 min at RT and washed 2 - 3 times with ice-cold PBS containing 
12.5 mM MgCl2. Prior to lysis cells were resupended in 3 x PCV of hypotonic Buffer A 
(chilled) and left swelling for 30 min on ice with occasional mixing. Complete lysis of cells 
but maintaining of intact nuclei was achieved by douncing 15 - 17 times (tight B pestle) on 
ice. After mixing with 1/10th volume of ice-cold Buffer B the nuclei were pelleted by 
centrifugating at 8000 rpm (SS-34 rotor) for 15 min at 4°C. 1.5 x PCV of ice-cold Buffer AB 
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was used to resuspend nuclei. Nuclei were lysed by adding 1/10th volume of 4 M (NH4)2SO4 
and the resulting extract was rotated for 20 min at 4°C. Ultracentrifugation at 38,000 rpm (Ti 
60 rotor) for 2 h at 4°C cleared the extract, which was then precipitated by slowly adding 
small amounts of total 0.3 g of solid (NH4)2SO4 per 1 ml extract. Precipitated proteins were 
centrifuged at 15,000 rpm (SS-34 rotor) for 15 min at 4°C and can be stored for up to one 
week at 4°C. The protein pellet was resuspended in 0.5 x volumes of ice-cold Buffer C and 
dialyzed 2 x 2 h against Buffer C. Insoluble material was removed by centrifugation at 16,000 
g for 5 min. Protease inhibitors were added again and the extract was quickly frozen as small 
aliquots in liquid nitrogen before long-term storage at -80°C. 
 
Buffer A: 10 mM Hepes/KOH pH 7.6   Buffer B: 50 mM Hepes/KOH pH 7.6 
10 mM KCl          1 M KCl 
2 mM MgCl2            30 mM MgCl2 
0.1 mM EDTA          0.1 mM EDTA 
1 mM DTT           0.2 mM DTT 
0.1 mM PMSF           40 M PMSF 
1 mM Na2S2O5        0.2 mM Na2S2O5 
Protease inhibitors (Aprotinin 1 g/ml, Leupeptin 1 g/ml, Pepstatin 0.7 
g/ml), DTT, PMSF and Na2S2O5 were added to Buffer A and B prior to use 
 
Buffer AB:  dilute Buffer B in Buffer A 1:10 
 
Buffer C: 25 mM Hepes/KOH pH 7.6 
  20% (v/v) Glycerol 
  150 mM KCl 
  12.5 mM MgCl2 
  0.1 mM EDTA 
  1 mM DTT 
  0.2 mM PMSF 
1 mM Na2S2O5 
Protease inhibitors (Aprotinin 1 g/ml, Leupeptin 1 g/ml, Pepstatin 0.7 
g/ml), DTT, PMSF and Na2S2O5 were added prior to use 
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4.5.3.2 Purification of FLAG-tagged MOF from SL2 nuclear extracts 
The nuclear extract was incubated with in chilled Buffer C equilibrated FLAG beads 
(Anti-FLAG M2 Agarose, Sigma) for 2 h at 4°C on a rotating wheel, whereby 40 l beads 
(which equals 80 l original slurry) were used per 300 l nuclear extract. All subsequent 
washing steps were carried out with ice-cold and at least 1 ml of buffer. The beads were two 
times washed briefly with Buffer C, followed by a third washing step with higher salt (400 
mM KCl) on the rotating wheel for 5 min at 4°C. In order to reduce non-specific interactions 
with the beads and with the FLAG-tagged proteins, another three washing steps for 10 - 15 
min on a rotating wheel in high-salt Wash Buffer was added. It follows a quick wash with 
lower salt (400 mM KCl) and three quick washes in Elution Buffer. The FLAG-tagged MOF 
complexes were then eluted for 2 h at 4°C on a rotating wheel in the presence of 0.5 mg/ml 
FLAG-Peptide (Sigma) in a total volume of 65 l per 25 l beads. Eluted complexes were 
removed from FLAG-beads by short centrifugation through Micro Bio-Spin columns (Bio 
Rad) and then rapidly frozen as small aliquots (5 l) in liquid nitrogen and finally stored at -
80°C.  
 
4.6 Reporter gene assays in insect and human cells 
4.6.1 Reporter gene assay in SL2 cells 
4.6.1.1 Transient transfection of reporter gene constructs 
Reporter gene assays in Drosophila melanogaster SL2 cells were performed as 
described in [92]. 0.25 x 106 cells were seeded the day before transfection in 12-well plates 
and incubated as described above. The following plasmids were transfected using the 
Effectene Reagent (Qiagen): 15 ng Renilla reporter construct, 315 ng reporter gene construct 
carrying the DBF12 or other binding site attached to an inducible firefly luciferase reporter 
gene, and 160 ng of an MSL2-VP16 activator construct. The plasmids were first mixed with 
75 l EC Buffer (Qiagen) then 3.9 l of Enhancer (Qiagen) per 490 ng of total DNA 
transfected was added and vortexed for 1 sec. After 5 min incubation at RT 9 l Effectene 
Reagent was added and vortexed for 10 sec. The DNA-Effectene complexes are formed at RT 
within 10 min and were carefully mixed with 400 l fresh medium before slowly added to 0.5 
x 106 cells in 800 l fresh medium per 12-well. After 2 days incubation at 26°C SL2 cells 
were lysed in order to analyze reporter gene activation.  
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4.6.1.2 Preparation of cell extracts from transiently transfected SL2 cells 
After 2 days the cells were harvested from the 6-well plate by pipetting and were 
pelleted by centrifugation for 10 min at 2000 rpm at 4°C. Cells were once washed with PBS 
before they were lysed in 100 l Passive Lysis Buffer (Qiagen) at 4°C with occasional 
mixing. Finally, cell debris were removed by centrifuging at 13,000 rpm for 2 min at 4°C and 
the supernatant was used on the one hand for measuring luciferase activities and on the other 
hand for detection of transfected MSL-VP16 proteins via Western blot. After usage, the 
extracts were frozen in liquid nitrogen and stored at -80°C.  
 
4.6.1.3 Measuring luciferase activities 
Luciferase activities were measured by using the Dual Luciferase Kit (Promega) 
according to the manufacture’s protocol. 20 l of cell extracts from transiently transfected 
SL2 cells were incubated for 2 min at RT in vials in order to reach RT. Then 95 l of LARII 
substrate was added and after another 2 min incubation at RT (but light protected) light 
emission of the firefly luciferase was measured using a luminometer (Berthold) and 5 ml 
polystyrene tubes (Sarstedt). Each measurement took 10 sec and was repeated 3 times. After 
mixing with 95 l of Stop and Glow Reagent the light emission of the Renilla luciferase was 
measured as above. Firefly luciferase activity was normalized to Renilla luciferase activity 
(normalized RLU). The ratio of the normalized RLU of MSL2-VP16 relative to the 
normalized RLU of the VP16 activation domain alone gives the fold induction, which can be 
seen as a measurement for the MSL2-VP16 recruitment to the reporter gene. Fold inductions 
are shown as the mean value plus and minus the standard deviation from several technical 
replicates and from at least two independent plasmid preparations. The expression of the 
MSL2-VP16 constructs was checked by Western blots using a rabbit anti-MSL2 antibody. 
 
4.6.2 Reporter gene assay in human HEK-293 cells 
4.6.2.1 Transient transfection of reporter gene constructs 
The day before transfection 0.1 x 106 cells were seeded in a 24-well plate in 0.5 ml 
medium and incubated as described above. The following plasmids were transfected: Renilla 
reporter construct (4 ng), a reporter construct carrying a binding site attached to an inducible 
firefly luciferase reporter gene (75 ng), MSL-VP16 activator constructs (varying amounts, see 
‘results’ section), pEGFP-N2 vector (25 ng) to estimate transfection efficiency and the 
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pBluescript KS+ cloning vector as ‘filler-DNA’. In total 1 g of plasmid DNA was diluted in 
50 l serum- and antibiotic-free medium and mixed with 2.5 l Fugene HD Reagent 
(Fugene:DNA ratio 5:2). After 20 min incubation at RT 25 l of the transfection mix was 
added slowly to the cells in a 24-well plate. After 2 days cells were harvested by pipetting and 
centrifuged at 400 g for 5 min at 4°C. After washing with PBS cells were lysed and luciferase 
activities were measured as described above for SL2 cells.  
 
4.7 Protein-DNA interactions 
4.7.1 Electrophoretic mobility shift assays (EMSA) 
Purified MSL proteins were incubated with sub-saturating concentrations of 
radiolabeled DNA or RNA fragments (< 0.2 nM, 5000 - 10000 cpm) in 50 mM Hepes/KOH 
pH 7.6, 100 mM KCl, 5% glycerol, 0.05% NP-40, 0.5 mM EDTA, 1 mM MgCl2 and 0.1 
g/l BSA (New England Biolabs) in a total volume of 12 l. The binding reactions were 
started by adding the MSL protein and were analyzed after 15 min incubation at 25°C on non-
denaturing 1.2% agarose gels (12 x 7 cm) in 0.5 x TBE. Alternatively, native PAA gels (0.5 x 
TBE, 5% (v/v) PAA (37.5:1), 0.05% (v/v) TEMED, 0.1% (v/v) APS) in the Novex Mini-Cell 
system (Invitrogen) were used when the small CXC protein was analyzed for DNA binding. 
The EMSA gels were pre-electrophoresed at 90 V for 20 min and, subsequently, the protein-
nucleic acid complexes were separated at 90 V for 50 - 60 min at 18 - 20°C. Gels were dried 
on anion exchanger chromatography and Whatman paper and radiolabeled nucleic acids were 
visualized by using a Phosphor-Imager (FujiFilm FLA-3000). For competition experiments 
MSL proteins were first incubated at a concentration close to their KD value (50 nM) with 
sub-saturating concentrations of radiolabeled DNA for 15 min at 25°C. Then unlabeled 
competitor DNA or RNA was added. After additional 20 min incubation at 25°C the reactions 
were analyzed by non-denaturing EMSA gels as described above. 
 
4.7.2 Calculation of affinity constants  
The scanned EMSA gels were analyzed with the Aida Image Analyzer Software. The 
signal of nucleic acid-bound protein (AB) and the signal of total nucleic acid (Atotal) were 
quantified and the fraction bound (AB/Atotal) calculated. Binding curves were obtained by 
performing non-linear regression with KaleidaGraph software and a standard bimolecular 
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model:  where y is the fraction bound, x is the concentration of protein, ABmax is 
the maximum of nucleic acid-bound protein and KD is the affinity constant. For competition 
experiments, first AB was calculated from the difference between the signal of total nucleic 
acid (Atotal) and the signal of free nucleic acid (Afree). Then the fraction bound was calculated 
(AB/Atotal) and normalized to the fraction bound measured at 0 nM competitor. Competition 
curves were obtained with the following competition model:  where y 
is the normalized fraction bound, x is the concentration of competitor, ABmax is the maximum 
of nucleic acid-bound protein at 0 nM competitor, IC50 is the half maximal inhibitory 
concentration and Hill Slope describes the steepness of the curve. Affinity constants and IC50 
values are shown as the mean value plus and minus the standard deviation from several 
technical replicates and from at least two independent protein preparations. 
 
4.8 Immunofluorescence staining on SL2 cells 
The protocol for immunofluorescence stainings is based on the protocol published by 
Morales et al. [75]. Microscope slides were washed in ddH2O and coated with Poly L-Lysin 
according to the manufacture’s protocol (Sigma). Per well (14 mm) 0.5 - 1.0 x 106 SL2 cells 
were seeded and allowed to settle for 2 h. The cells were then washed briefly with ice-cold 
PBS and fixed in 2% (v/v) formaldehyde in PBS for 7 min on ice. Afterwards cells were 
permeabilized in 1% (v/v) formaldehyde and 0.25% (v/v) Triton X in PBS for 7.5 min on ice 
and then 2 x washed in ice-cold PBS. All subsequent steps were performed at RT. Unspecific 
binding sites were blocked with Blocking Solution (1 x PBS, 2% (w/v) BSA (Sigma), 5% 
(v/v) FBS) for 1 h at RT. After blocking the microscope slides were incubated for 1 h with an 
appropriate dilution of the primary antibody in blocking solution. Before and after the 
incubation in Blocking Solution for an additional hour with secondary antibodies, the cells 
were washed two times with PBS. DNA was counterstained with DAPI and mounted using 
Moviol. Pictures were taken with a Zeiss Axiovert microscope (67x oil immersion objective) 
coupled to a CCD Camera (AxioCamMR, Zeiss). Images were level-adjusted in Adobe 
Photoshop CS4. 
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6 Appendix 
6.1 Abbreviations 
Å     Angstrom 
A     Adenine 
A280     Absorption at 280 nm 
ac     Acetylation   
Amp     Ampicillin 
APS     Ammonium persulfate 
ATP     Adenosin triphosphate 
bp      Basepairs 
BSA      Bovine serum albumin 
C      Cytosine 
°C      Degree Celsius 
Cam      Chloramphenicol 
CAPS      N-cyclohexyl-3-aminopropanesulfonic acid 
cDNA      Complementary DNA 
cds      Coding sequence 
CES      Chromatin entry sites 
ChIP      Chromatin immunoprecipitation 
Ci      Curie 
cpm      Counts per minute 
CV      Column volume 
Da      Dalton   
dATP      Desoxyadenosin triphosphate 
dCTP      Desoxycytosin triphosphate 
ddH20      Double distilled water 
dGTP      Desoxyguanosin triphosphate 
dH2O      Distilled water 
DAPI      4’,6-diamidino-2-phenylindole 
DBF      DCC binding fragment 
DBD      DNA binding domain 
DCC      Dosage compensation complex 
DHS      DNase hypersensitive site 
DMSO      Dimethyl sulfoxide 
DNA      Desoxyribonucleic acid 
dNTP      Desoxyribonucleotide triphosphate 
DTT      Dithiothreitol 
dTTP      Desoxythymidin triphosphate 
ds      Double stranded 
EDTA      Ethylendiamintetraacetate 
EMSA      Electrophoretic mobility shift assay 
EtOH      Ethanol 
FBS      Fetal bovine serum  
FPLC      Fast protein liquid chromatography 
FRAP      Fluorescence recovery after photobleaching  
fw      Forward 
g      Gravities 
G      Guanine 
GFP      Green fluorescent protein 
GST      Glutathione-S-transferase 
h      Hours 
HAS      High affinity site 
HAT      Histone acetyltransferase 
HEPES      4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP      Horseradish peroxidase 
HTH      Helix-turn-helix 
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IC50       Half maximal inhibitory concentration 
IF      Immunofluorescence 
IPTG      1-isopropyl--D-1-thiogalacto-pyranoside 
IR      Infrared 
ISWI      Imitation switch  
K      Lysine  
kbp      Kilobasepairs 
KD      Affinity constant 
kDa      Kilodalton 
LB      Lauria-Bertani 
M      Molar 
mA      Milliampere 
mAU      Milli absorbance units 
me      Methylation 
MeOH      Methanol 
mcs      Multiple cloning site 
min      Minutes 
MOPS      3-(N-morpholino)propanesulfonic acid 
MPa      Megapascals 
MRE      MSL recognition element 
MSL      Male-specific lethal 
NP-40      Nonidet P-40 
nt      Nucleotides 
o/n      Overnight 
OD600      Optical density at 600 nm 
32P      Radioactive phosphorus isotope 32P 
PAA      Polyacrylamide 
PAGE      Polyacrylamide gel electrophoresis 
PBS      Phosphate buffered saline 
PCR      Polymerase chain reaction 
PCV      Packed cell volume 
PMSF      Phenylmethanesulfonyl fluoride 
psi      Pounds per square inch 
PVDF      Polyvinylidene fluoride 
RLU      Relative luciferase units 
RNA      Ribonucleic acid 
RNAi      RNA interference 
rpm      Revoltations per minute 
rRNA      ribosomal RNA 
RT      Room temperature 
rv      Reverse 
SDS      Sodium dodecyl sulfate 
sec      Seconds 
ss      Single stranded 
T      Thymine 
TBE      Tris borate EDTA buffer 
TCA      Trichloroacetic acid 
TEMED      N,N,N’,N’-Tetramethylethylenediamine 
TFO      Triplex forming oligonucleotide 
Tris      Tris(hydroxymethyl)aminomethane 
U      Uracil 
UAS      Upstream activator sequence  
ub      Ubiquitylation 
V      Volts 
VP16-AD     Herpes simplex viron protein 16 activation domain 
v/v      Volume per volume 
WB      Western Blot 
wt      Wildtype 
w/v      Weight per volume 
Xa      active X chromosome 
Xi      inactive X chromosome 
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